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Abstract 
Diabetes is a major cause of morbidity, mortality and health care spending 
worldwide. Despite the vast amount of resources spent on health education 
and various disease management programs to prevent the disease, the incidence 
and prevalence of diabetes still continue to grow, particularly in the Asia-
Pacific region. According to existing data, the diabetic population in this 
region is about 47.3 million which is the largest in the world and it also 
accounts for 46% of the global burden of the disease. 
In Hong Kong, the prevalence of Type 2 diabetes mellitus (DM) is about 9.8%, 
suggesting about 500,000 local residents out of a population of 6.8 million in 
2004, are suffering from the disease with a very high prevalence rate in the 
elderly. It increases with age to 29.3% in women and 21.7% in men who are 
65-74 years old. With the increasing westernization of the life style and the 
rapid growth of aging population in recent years, it is anticipated that the 
incidence and prevalence of the disease will continue to rise and hence will 
translate into a significant overall economic burden to the society. Patients 
with diabetes are at higher risk for the development of various acute 
complications such as diabetic ketoacidosis, hyperglycemic coma, and life-
threatening hypoglycemia, and also a variety of chronic complications 
including cardiac, renal, ophthalmic, neurological and skin disorders. 
Moreover, diabetes itself is the eighth leading cause of death in Hong Kong and 
it is an important risk factor for heart and cerebrovascular diseases. Therefore, 
because of the chronic nature and high complication rate of the disease, it can 
V 
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pose a major economic burden to the society. Due to the unique health care 
financing system in Hong Kong, where over 88% of the total medical expenses 
in public hospitals is shouldered by the government, the need to study the cost 
impact of chronic diseases with multiple complications such as diabetes is 
therefore imminent. 
This study aims to estimate the total economic burden of Type 2 diabetic 
patients attending a public hospital to the Hong Kong society using a 
prevalence-based cost-of-illness approach. A retrospective cohort 
observational study was conducted. The direct medical costs in a public 
hospital were collected from a hospital electronic database, the Clinical 
Management System. The other direct costs and indirect costs were evaluated 
using a Chinese questionnaire developed by the author. The total figure from 
this study was then extrapolated to estimate the economic burden for the total 
Type 2 diabetic population in Hong Kong. The results from this study would 
identify major cost drivers in managing type 2 diabetic patients and hence 
would contribute in formulating healthcare financing plans associated with the 
disease. 
Two hundred and four Type 2 DM patients who attended the diabetes mellitus 
outpatient clinic at a public hospital from Jan 2004 to May 2004 were randomly 
selected and invited to join this study and 147 Type 2 DM patients were 
subsequently enrolled. The response rate was 72%. Forty-five percent of 
patients were male with a mean age of 63 years old, and the mean duration of 
the disease was 13.7 years. Fifty-three percent of patients had hypertension; 
33.3% had dyslipidemia; 37.4% were over-weighed or obese; 10.9% were 
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smokers; and 21.8% were at risk of foot problems. 44.9% of patients had 
different types of complications: 28.6% patients had microvascular 
complications only, i.e. retinopathy, or nephropathy; 6.1% had macrovascular 
complications only, i.e. coronary heart disease, stroke or peripheral vascular 
disease; 10.2% had both microvascular and macrovascular complications. 
Annual total cost for a Type 2 DM patient was HK$13,457 土 15，943 with direct 
cost accounted for more than 87.9%. The government was the major payer 
who paid for over 78.4% of the total costs. Annual total direct medical costs per 
patient was HK$11,638 士 13,386 in which the government was shouldering 
90.6% of the total direct medical costs. Among the government direct 
medical costs, government specialist outpatient clinic visit costs and inpatient 
costs were the major cost drivers, which contributed up to 39.6% and 43.0% of 
the cost, respectively. 
The direct medical costs increased dramatically if the patient had complications. 
When the patient developed microvascular or macrovascular complications 
only, the costs increased by 1.1 times, compared with those without 
complication. If the patient had both microvascular and macrovascular 
complications, the costs would be 1.3 times compared with those without 
complication. The total government direct medical cost for those without 
complication was HK$9,781 per year. When the patient developed both 
microvascular and macrovascular complications, the cost would increase to 
HK$13,193 per year. 
Type 2 DM was found to have a significant impact on local healthcare budget. 
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With about 210,000 diagnosed Type 2 DM patients in Hong Kong in 2004，the 
annual total direct medical costs were estimated to be HK$2,444 million which 
contributed to about 3.9% of the total Hong Kong healthcare expenditure. 
Assuming 93.6% of Type 2 DM patients were now using the Hospital 
Authority (HA)'s healthcare services, number of Type 2 DM patients using HA 
healthcare service would be about 196,560. The total direct medical costs of 
Type 2 DM patients incurred at the HA was estimated to be HK$2,074 million, 
which contributed up to 6.4% of the HA's healthcare expenditure in 2004. 
We developed an economic model that incorporated both the glycaemic goals 
recommended by the American Diabetes Association, and the algorithm of the 
UK Clinical Guidelines for the management of blood glucose in Type 2 DM 
patients, in order to project and evaluate the cost-effectiveness in short-term (2-
year) for two different combination strategies (metformin [M] + rosiglitazone 
[R], and metformin + glibenclamide [G]) for patients whose diabetes could not 
be adequately controlled by metformin alone. Based on the results of our 
decision analysis model, with its underlying assumptions and data, combination 
therapy M+G was more cost-effective than M+R. The cost per controlled 
Type 2 DM patient for M+R was HK$ 17,645 while that for M+G was 
HK$ 11,909 in 2-year period. The incremental cost was HK$5，736. These 
findings should be re-evaluated as soon as additional evidence becomes 




























我們在2 0 0 4年1月至5月隨機抽出2 0 4名在一間公營醫院接受門診治療 
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Chapter 1. Introduction 
Almost 500,000 Hong Kong people have Type 2 diabetes. It is a major cause 
of morbidity, mortality and health care spending worldwide. Globally, the 
total number of people with diabetes is projected to rise from 171 million in 
2000 to 366 million in 2030. The rise is particularly significant in the Asia-
Pacific region. According to existing data, the diabetic population in this 
region is about 47.3 million which is the largest in the world and it also 
accounts for 46% of the global burden of the disease.^^ Despite this, the local 
financial burden of this common and non-communicable disease was never 
investigated. Although costing data of Type 2 DM in several countries, such 
as the USA, Europe and Australia, are available, they cannot be readily applied 
locally due to variations in health care funding and service delivery systems. 
To have an economic and social impact on the burden of diabetes, resources 
need to be allocated efficiently and effectively to offset costs in other areas. 
To inform this decision making, comprehensive estimates of the costs, the 
parties who bear the costs and the attribution of these costs need to be 
established. 
The UK Prospective Diabetes Study (UKPDS) indicated that after 3 years, only 
50% of Type 2 DM patients were adequately controlled with a single 
antidiabetic agent, and after 9 years, this percentage had decreased to 25%'. 
Is addition of which antidiabetic agent, SU or TZD more cost-effective, if the 
patient's diabetes cannot be adequately controlled by metformin alone? We 
have developed a short-term (2-year period) decision analysis model, in order 
• 1 
Chapter 1 
to compare the cost-effectiveness of Rosiglitazone-based combination therapy 
(i.e. Metformin + Rosiglitazone) with the most commonly used alternative 
therapy (i.e. Metformin + Glibenclamide) for the treatment of Type 2 DM 
patients whose diabetes is not adequately controlled by metformin alone, with 
the aim of informing decision makers in payer's (i.e. the Hospital Authority -
the HK Government) perspective. 
• 2 
Chapter 2 
Chapter 2. Literature Review 
2.1 Diabetes Mellitus (DM): Overview 
Diabetes mellitus is a group of metabolic diseases characterized by chronic 
hyperglycemia resulting from insulin deficiency, insulin resistance, or both. The 
effects of diabetes mellitus include long-term damage, dysfunction, and failure 
of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels. 
Diabetes mellitus may present with characteristic symptoms such as thirst, 
polyuria, blurring of vision and weight loss. In its most severe forms, 
ketoacidosis or no-ketotic hypersomolar state may develop and lead to stupor, 
coma, and in absence of effective treatment, death. The symptoms are often 
not severe, or may be absent, and consequently hyperglycaemia sufficient to 
cause pathological and functional changes may be present for a long time 
before the diagnosis is made. The long-term effects of diabetes include 
progressive development of the specific complications of retinopathy with 
potential blindness, nephropathy that may lead to kidney failure, neuropathy 
with risk of foot ulcers, and amputations. People with diabetes are also at 
increased risk of cardiovascular, peripheral vascular and cerebrovascular 
disease.^ In 2000，3.2 million people died from complications associated with 
diabetes.3 These complications account for a lot of social and financial 
burden of diabetes. 




These range from autoimmune destruction of the B-cells of the pancreas with 
consequent insulin deficiency to abnormalities that result in resistance to insulin 
action. The basis of the abnormalities in carbohydrate, fat, and protein 
metabolism in diabetes is deficient action of insulin on target tissues. Deficient 
insulin action results from inadequate insulin secretion and/or diminished tissue 
responses to insulin at one or more points in the complex pathways of hormone 
action. Impairment of insulin secretion and defects in insulin action frequently 
coexist in the same patient, and it is often unclear which abnormality, if either 
alone, is the primary cause of the hyperglycemia.* 
2.1.1 Diagnosis and Diagnostic Criteria 
According to World Health Organization (WHO)'s recommendations, the 
clinical diagnosis of diabetes is often prompted by symptoms such as increased 
thirst and urine volume, recurrent infections, unexplained weight loss, and in 
severe cases, drowsiness and coma; high levels of glycosuria are usually 
present. A single blood glucose estimation of the excess diagnosis values 
indicated in Table 1 establishes the diagnosis in such cases. For clinical 
purposes, an Oral Glucose Tolerance Test (OGTT) to establish diagnostic status 
need only be considered if causal blood glucose values lie in the uncertain 
range (i.e. between the levels that establish or exclude diabetes) and fasting 









Glucose concentration，mmol'' (mg d”） 
Whole blood Plasma 
Venous Capillary Venous Capillary 
Diabetes Mellitus 
Random > 10.0(180) > 11.1 (200) > 11.1 (200) > 12.2 (220) 
Fasting or >6.1 (110) >6.1 (110) >7.0(126)' ," >7.0(126) 
2-h post glucose load > 10.0(180) > 11.1 (200) > 11.1 (200) > 12.2 (220) 
Impaired Glucose 
Tolerance (IGT) 
Fasting and <6.1 (110) <6.1 (110) <7.0(126) <7 .0(126) 
2-h post glucose load >6.7(120) >7.8(140) >7.8(140) >8 .9(160) 
Impaired Fasting 
Glycaemia (IFG) 
Fasting and > 5.6 (100) > 5.6 (100) > 6.1 (110)> 6.1 (110) 
and < 6.1 and < 6.1 and < 7.0 and < 7.0 
(110) (110) (126) (126) 





For epidemiological or population screening purposes, the fasting or 2-h value after 75 g oral 
glucose may be used alone. For clinical purpose, the diagnosis of diabetes should always be 
confirmed by repeating the test on another day unless there is unequivocal hyperglycaemia with 
acute metabolic decompensation or obvious symptoms. 
In the Hong Kong Chinese, the fasting plasma glucose cut-off value that 
corresponds to a 2-h plasma glucose level of 11.1 mmol/L is between 5.5 and 
5.8 inmoI-i.4，5 
In Hong Kong, GTC Ko recommended that in symptomatic patients, a fasting 
plasma glucose (PG) or random PG measurement could be used to diagnose 
diabetes using the WHO criteria. A second measurement on a separate day is 
required to confirm the diagnosis before clinical management is started. In 
epidemiological surveys, either a fasting PG or 2-hour PG measurement after 
an OGTT can be used. In some selected high-risk groups, which include those 
with a history of Impaired Glucose Tolerance or Impaired Fasting Glucose, or 
those with fasting PG > 5.6 mmol"' and HbAic > 5.5%, an OGTT is the 
preferred choice of test.? 
Juliana CN Chan, et al.'s recommendations on diagnosis of diabetes mellitus in 
o 




Figure 1: Diagnosis of diabetes mellitus? 
Patient? risk: Symptoms sf distiatss: 
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or ting PC 27.0 mrT>ol/U 
1 
<0.0 mmaifL 7.0^ 11.1 mirwI/L 6.0-R.Q mmolA. 
i 1 i Impaired Castlno glyoerrva (iFG) r 
Perform •？5g OGTT 
. • Diat>etes unlikely t Classify aoconfing to ihi WHO critwia ^ Diabetes ntellitus* 
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low risk subjflct£ at»dfor 2h-PG sll.1 mmcll. 
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» Test FPG Of i»rfonn 75 g OGTT yearly 
I^n asymptomatic subjects, two 日bnormaJ values are required for the diagnosis and cBnfcaf managsment of diabetes. 
GDM gestational diabetes me冊us: BP � blood pressure: OGTT = oral glucose tol»ranca test; WHO-World 
Health Organization; FPG-fasting plasma glucose 
2.1.2 Classifications of Diabetes Mellitus 
Diabetes Mellitus can be classified as two main aetiological types, i.e. Type 1 
and Type 2 diabetes mellitus. Both Type 1 and Type 2 DM are heterogeneous 
diseases with environmental and genetic determinants. Type 1 DM mainly 
affects young people. Type 2 DM, which is an extremely heterogeneous 




In many ethnic populations other than white, it is also the predominant form of 
diabetes even among patients with young onset of disease (e.g. < 40 years). 
Common symptoms of Type 1 DM include: excessive secretion of urine 
(polyuria), thirst (polydipia), weight loss and tiredness. These symptoms may 
occur suddenly. People with Type 2 DM may have similar, but less obvious, 
symptoms. Many have no symptoms and are only diagnosed after many years 
of onset. As a consequence, almost half of all people with Type 2 diabetes are 
not aware that they have this disease until they have complications. 
Figure 2: Disorders of glycemia: etiologic types and stages' 
Stages Normoglycemia Hyperglycemia 
Types Normal U^COM regul*li*n Impairtd Glucose Tolerance ： DUbeic* Mdlilus 
X . or i 
Impaired Fasting GIucom ： Nociaauio tanilia TEQUICMT HSDIArai|aina蕭 
4Prr-I)iubclrs) ： faowwM (bcMrvivit 
.^mm^mmmmmmmmmmm^m^^mmmmmmmmmmmmmmmmm^mm^m^ 
TVpe 1* i 
Type! • I 
Other Spedlk Typ«** -^ fmmmmmm^ m ^ ^rn^^mmmmmmmmmmmm^ 
Gestational Dhbdei ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
2.1.2.1 Type 1 Diabetes Mellitus 
Type 1 indicates the processes of beta-cell destruction that may ultimately lead 




development of ketoacidosis, coma and death. It is usually characterized by 
the presence of antibodies to glutamic acid decarboxylase (GAD), islet cell or 
insulin antibodies which identify the autoimmune processes that lead to beta-
cell destruction. The rate of destruction is quite variable, being rapid in some 
individuals and slow in others.^ The rapidly progressive form is commonly 
observed in children, but also may occur in adults .� The slowly progressive 
form generally occurs in adults and is sometimes referred as latent autoimmune 
diabetes in adults (LADA). There are some forms of Type 1 diabetes which 
have no know aetiology. Some of these patients have permanent 
insulinopenia and are prone to ketoacidosis, but have no evidence of 
autoimmunity. This form of diabetes is more common among individuals of 
African and Asia origin. 
Type 1 DM accounts for only 5-10% of those with diabetes in whites, which is 
one of the most important chronic diseases of children in North America and 
Europe. In Finland, the incidence of Type 1 DM is as high as 29.5 per 
100,000 per year" However, it is relatively uncommon in Asian populations. 
Only 1.7 per 100,000 per year is diagnosed to have Type 1 DM in J a p a n � I n 
Hong Kong Chinese, the incidence of Type 1 DM is also very low, which is 
estimated at 2.0 per 100,000 per year'^ and less than 3% of adult patients can 
be considered to have classic Type 1 DM. As a result, our study is focused at 
the cost of Type 2 DM only. 




Patients with Type 2 DM cannot use insulin effectively. They can sometimes 
manage their conditions by lifestyle change alone, but oral drugs are often 
required, and less frequently insulin, in order to achieve good glycemic control. 
They have similar, but less obvious symptoms than those with Type 1 DM, 
Many have no symptom and are only diagnosed after many years of onset, 
when complications are already present. There are probably many different 
causes of this form of diabetes. Although the specific etiologies are not known, 
autoimmune destruction of B-cells does not occur. 
The majority of Type 2 DM patients are obese and obesity itself causes or 
aggravates insulin resistance. An increased percentage of body fat distributed 
predominantly in the abdominal region is often found. 
Ketoacidosis is infrequent in this type of diabetes. However, patients with this 
form of diabetes may have insulin levels that appear normal or elevated, the 
high blood glucose levels in these diabetic patients would be expected to result 
in even high insulin values had their beta-cell function been normal. Thus, 
insulin secretion is defective and insufficient to compensate for the insulin 
resistance. On the other hand, some individuals have essentially normal 
insulin action, but markedly impaired insulin secretion. Insulin sensitivity 
may be increased by weight reduction, increased physical activity, and/or 




Figure 3: The pathogenesis of Type 2 diabetes mellitus^ 
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Type 2 DM is the predominant form of diabetes worldwide, which accounts for 
90-95% of those with diabetes. The risk of developing Type 2 diabetes 
increased with age, obesity, and lack of physical activity. It occurs more 
frequently in women with prior gestational diabetes and in individuals with 
hypertension or dyslipidaemia. Its frequency varies in different racial/ethnic 
subgroups. It is often associated with strong familial, likely genetic, 
predisposition. However, the genetics of this form of diabetes are complex 
and not clearly defined] In summary, people with the following factors are at 
greater risk of Type 2 DM: 
> People over age 45 




> People who are overweight 
> People who do not exercise regularly 
> People with low high-density lipoprotein (HDL) cholesterol or high 
triglycerides 
> Certain racial and ethic groups (e.g. African Americans, Latinos, Asian 
and Pacific Islanders, and Native Americans) 
> Women who had gestational diabetes, a form of diabetes occurring in 2-
5% of all pregnancies, or who have had a baby weighing 9 pounds or more 
at birth 
2.1.2.3 Other Types of Diabetes 




Table 2: Etiologic classification of diabetes mellitus^ 
I. Type 1 diabetes (p-cell destruction, usually leading lo absolute insulin deficiency� 
A. Immune mediated 
B. Idiopathic 
II. Type 2 diabetes (may range from predonilnanlly insulin resistance with relative insulin deficiency to a 
prcciorairKintly secretory defect with insulin resistance) 
III. Other specific types 
A. Gcnelic defects of p-cell function 
1. Chromosome 12, HNF- la (M0DY3) 
2. Chromosome 7, glucokinase (MODY2) 
3. Chromosome 20, HNF-4a (MODYl) 
4. Chromosome 13, insulin promoter factor-1 (IPF-1; MODY4) 
3. Chromosome 17. HNF- lp (MODY3) 
6. Chromosome 2’ Nfu/oDl (MODY6) 
7. MKochcmdrial DNA 
8. Others 
B. Genetic defects in insulin action 
1. Type A Insulin resistance 
2. Lcprechauiiism 
3‘ RaDson-Mendenhall syndrome 
4. Lipoatrophic diabetes 
3. Others • 
C. Diseases of the exocrine pancreas 
1. Pancreatitis 
2. 了 n a u r a a / p i n c r e a i e c t o m y 
3. Neoplasia 
4. Cystic fibrosis 
5. Hemochromalosis 











E. Drug- or chemical-induced . 
1. Vacor 
2. Peniamidine 
3. Nicotinic acid 
4. Glucocorticoids 
Thyroid hormone 
6. Diaz oxide 
7. (3-adrenergic agonists 





1. Congenital rubella 
2. Cytomegalovirus 
3. Others 
G. Uncommon forms of immune-mediated diabetes 
1. ^Stiff-man" syndrome 
2. AntWnsulin receptor antibodies 
3. Others 
H. Other genetic syndromes sometimes associated with diabetes 
1. Down's syndrome 
2. Kllnefelter's syndrome 
3. Turner's syndrome 
4. Wolfram's syndrome 
！5. Friedreich's ataxia 
6. Hunllnglon's chorea 
7. Laurence-Moon-Biedl syndrome 
8. Myotonic dystrophy 
9. Porphyria 
10. Prader-Willi syndrome 
11. Others 
IV. Gestational diabetes mellitus (GDM) 
Patients with any form of diabetes may require insulin treatment al some stage of their disease. Such use of 




2.1.3 Management of Type 2 Diabetes Mellitus 
American Diabetes Association recommended that people with diabetes should 
receive medical care from a physician-coordinated team. Such teams may 
include, but are not limited to, physicians, nurse practitioners, physician's 
assistants, nurses, dietitians, pharmacists, and mental health professionals with 
expertise and a special interest in diabetes. It is essential in this collaborative 
and integrated team approach that individuals with diabetes assume an active 
role in their care. 
The management plan should be formulated as an individualized therapeutic 
alliance among the patient and family, the physician, and other members of the 
health care team. Any plan should recognize diabetes self-management 
education as an integral component of care. In developing the plan, 
consideration should be given to the patient's age, school or work schedule and 
conditions, physical activity, eating patterns, social situation and personality, 
cultural factors, and presence of complications of diabetes or other medical 
conditions. Implementation of the management plan requires that each aspect is 
understood and agreed on by the patient and the care providers and that the 
goals and treatment plan are reasonable” 
2.1.3.1 Diet and Exercise 




most Type 2 DM patients, carbohydrates should provide 50% to 60%, protein 
no more than 15%, and total fat 30% to 35% of total daily energy requirement. 
Approximately one-third of the daily dietary fat intake should be 
polyunsaturated, one-third unsaturated, and one-third, saturated. 
Alcohol contains calories and may increase plasma TG It also inhibits 
gluconeogenesis and can cause spontaneous hypoglycemia, as well as delayed 
recovery from drug-induced hypoglycemia. Thus, although small amounts of 
alcohol may be allowed, it should be followed by ingestion of food to prevent 
hypoglycemia. 
To maximize the effects of dieting, physical activity should be maintained or 
increased. Regular exercise has been shown to improve glucose control, 
reduce cardiovascular risk factors, contribute to weight loss, and improve well-
being. 
2.1.3.2 Smoking Cessation 
Cigarette smoking contributes to one of every five deaths in the U.S. and is the 
most important modifiable cause of premature death. Studies with diabetes 
consistently found a heightened risk of morbidity and premature death 
associated with the development of macrovascular complications among 
smokers. Smoking is also related to the premature development of 
microvascular complications of diabetes and may have a role in the 
development of Type 2 diabetes. As a result, the American Diabetes 




cessation counseling and other forms of treatment as a routine component of 
diabetes care.'^ 
2.1.3.3 Glycemic Control 
Glycemic control is very important for diabetes patients. Findings from three 
landmark studies: the Diabetes Control and Complications Trial ， the 
Kumamoto S t u d y a n d the United Kingdom Prospective Diabetes Study 
(UKPDS)16，suggested that maintaining glucose concentrations as close to 
normal as possible in both type 1 and type 2 DM decreases the incidence of 
microvascular complications. In the UKPDS, 4209 newly diagnosed Type 2 
DM patients were randomized to either intensive (medication) or conventional 
(diet) treatment and observed for approximately 10 years. The intensive-
treatment group underwent a subsequent randomization to primary therapy with 
sulfonylurea (SU) or insulin. When compared with conventional therapy, 
intensive treatment was associated with decreased risk of predominantly 
microvascular complications, including a 12% reduction in any diabetes-related 
end point (p=0.03) and a 25% reduction in all microvascular end points 
(p<0.01). There was no significant effect on diabetes-related death or on all-
cause mortality, however, and there was only a trend toward myocardial 
infarction (p=0.05). Overall, there were no significant differences between 
SU-treated subjects and those treated with insulin. 
In Hong Kong, the recommended glucose target is with fasting plasma glucose 
4-6 mmol/L, or with HbAic < 6%. With few exceptions, the available oral 




Their mechanisms of actions are different, which are illustrated in Figure 4. 
However, as a result they appear to have distinct metabolic effects. These are 
reflected in their adverse effect profiles and their effect on cardiovascular risk. 
Advantages and disadvantages of various oral antidiabetic agents are 
summarized in Table 3. 
Figure 4: Pharmacological approaches to the major metabolic defects of Type 2 Diabetes 
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Table 3: Currently available oral therapeutic options for Type 2 Diabetes Mellitus'^ 
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The UKPDS demonstrated after 3 years, only 50% of Type 2 DM was 
adequately controlled with a single antidiabetic agent, and after 9 years, this 
percentage had decreased to 25%'^. Each clinical trial that has examined the 
addition of an oral agent to that of another class has demonstrated additive 
HbAic reduction. The most popular combinations are SU and metformin, 
metformin and thiazolidinediones (TZD), and SU and TZD. 
2.1.3.4 Blood Pressure Control 




diabetes, affecting the majority of people with diabetes, depending on type of 
diabetes, age, obesity, and ethnicity. Hypertension is also a major risk factor for 
CVD and microvascular complications such as retinopathy and nephropathy. In 
type 1 diabetes, hypertension is often the result of underlying nephropathy. In 
type 2 diabetes, hypertension may be present as part of the metabolic syndrome 
(i.e., obesity, hyperglycemia, dyslipidaemia) that is accompanied by high rates 
of CVD. 
Randomized clinical trials have demonstrated the benefit (reduction of CHD 
events, stroke, and nephropathy) of lowering blood pressure to <140 mmHg 
systolic and <80 mmHg diastolic in persons with diabetes2�’2i 2,23 Therefore, a 
target blood pressure goal of <130/80 mmHg is reasonable if it can be safely 
achieved. Many patients require three or more drugs to reach target goals. 
Clinical benefits and potential adverse effects of various antihypertensive 
agents in diabetic patients were listed in Table 4. 
Lowering of blood pressure with regimens based on antihypertensive drugs, 
including ACE inhibitors, angiotensin receptor blockers (ARBs), B-blockers, 
diuretics, and calcium channel blockers, has been shown to be effective in 
lowering cardiovascular events. Several studies suggest that ACE inhibitors 
may be superior to dihydropyridine calcium channel blockers (DCCBs) in 
reducing cardiovascular events '^^ '^ .^ Additionally, recent data in people with 
diabetic nephropathy indicate that ARBs may be superior to DCCBs for 
reducing cardiovascular events ^^. Conversely, in the recently completed 
International Verapamil Study (INVEST) of more than 22,000 people with 
coronary artery disease and hypertension, the nondihydropyridine calcium . 
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channel blocker, verapamil, demonstrated a similar reduction in cardiovascular 
mortality to a B-blocker. Moreover, this relationship held true in the diabetic 
subgroup27. 
ACE inhibitors have been shown to improve cardiovascular outcomes in high-
cardiovascular-risk patients with or without hypertension^^'^^. In patients with 
congestive heart failure, ACE inhibitors are associated with better outcomes 
when compared with ARBs. ARBs also improve cardiovascular outcomes in 
the subset of patients with hypertension, diabetes, and end-organ injury^®. The 
compelling effects of ACE inhibitors or ARBs in patients with albuminuria or 
renal insufficiency provide additional rationale for use of these agents. 
•21 
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Table 4: Use of antihypertensive agents in diabetic patients' 
？Stl^?S^iSffffl，BniB!3SiMililiiSHiinmillil!i{SBlBEB33sffll 
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ipias巾a creatinine 120-260 则 o l A } . 
ESI^ D = end-stage renal disease 




Patients with type 2 diabetes have an increased prevalence of lipid 
abnormalities that contributes to higher rates of CVD. Lipid management aimed 
at lowering LDL cholesterol, raising HDL cholesterol, and lowering 
triglycerides has been shown to reduce macrovascular disease and mortality in 
patients with type 2 diabetes, particularly those who have had prior 
cardiovascular events. 
In studies using HMG (hydroxymethylglutaryl) CoA reductase inhibitors 
(statins), patients with diabetes achieved significant reductions in coronary and 
cerebrovascular events^^' 34，35’ 36 ^^ (wo studies using the fibric acid derivative 
"1*7 TO 
gemfibrozil, reductions in cardiovascular end points were also achieved ’ . 
The Heart Protection Study demonstrated that in people with diabetes over the 
age of 40 with a total cholesterol >135 mg/dl, LDL reduction of 30% from 
baseline with the statin, simvastatin was associated with an 25% reduction in 
the first event rate for major coronary artery events independent of baseline 
LDL, preexisting vascular disease, type or duration of diabetes, or adequacy of 
glycemic contropo. Therefore, in patients over the age of 40，statin therapy 
should be routinely considered. In patients with LDL >130 mg/dl, initial 
therapy with both lifestyle intervention and a statin is indicated. In patients with 
LDL between 100 mg/dl (2.60 mmol/1) and 129 mg/dl (3.30mmol/l), a variety 
of treatment strategies are available, including more aggressive nutrition 
intervention or pharmacological treatment with a statin. If the HDL is <40 
mg/dl and the LDL is between 100 and 129 mg/dl, a fibric acid derivative or 




Figure 5: Management of dyslipidemia in Type 2 diabetes mellitus? 
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In conclusion, recommended target values for control of risk factors in diabetic 
patients in Hong Kong are listed in Table 5. 
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Table 5: R e c o m m e n d e d target va lues fo r control o f r isk fac tors in d iabe t ic pat ients in H o n g 
K o n g ' 
M H ^ H H ^ ^ ^ H H m H B I H I H I ^ H n i m M B H I H H H H I M B I I I i 
Fasting plasma glucose, rrmolA. 4-6 
HbAn {xtipper limit of normal range), <100 (69 <6) 2:130 (eg i S ) 
Body mass indax, kg/m' <23 2:27 
Waist circumfe.'-ence, cm {ir>di) 
r/ale <75 « 3 0 ) 乏90(&3S> 
l-emale <70 f<28) >80 (32) 
Systolic blood pressure, mm Hg “ <135 ^160 
Diastolic blood pressure, mn> Hg <35 之95 
Totof cholesterol, i rmol / l <4.5 ^6,2 
HDL-C, mmcl/L >^^ <0.9 
LDL-C, mmol/L <2.6 ^4.2 
Triglyceride, rnmol/l <1.5 2:2.8 
* Adjust tT«atment goals depending (w age, coexisting conplicst'ons, and risk factors 
fHbAic as measured by c^ iromato^ raphic m^ thocts 
HDl-C = high-ddnsity lipoprotein cholesterol; LDL-C « low-df^r^iry lipoprotein cholesterol 
2.1.3.6 Anti-platelet Agents 
Aspirin has been recommended as a primary^^' 4 � a n d secondary therapy to 
prevent cardiovascular events in diabetic and nondiabetic individuals. One large 
meta-analysis and several clinical trials demonstrate the efficacy of using 
aspirin as a preventive measure for cardiovascular events, including stroke and 
myocardial infarction. Many trials have shown an 30% decrease in myocardial 
infarction and a 20% decrease in stroke in a wide range of patients, including 
young and middle-aged patients, patients with and without a history of CVD, 
males and females, and patients with hypertension. 




Diabetes is a life-threatening disease. In 2000, 3.2 million people died from 
complications associated with diabetes. Diabetes has become one of the 
major causes of premature illness and death in most countries, mainly through 
the increased risk of cardiovascular disease (CVD). CVD is responsible for 
between 50% and 80% of deaths in people with diabetes. In addition, diabetes 
is also the leading cause of blindness, amputation, and kidney failure. 
Although diabetes is sometimes considered a condition of developed countries, 
the loss of life from premature death among persons with diabetes is greatest in 
developing countries. The burden of premature death from diabetes is similar 
to that of HIV/AIDS, yet the problem is largely unrecognized.^ These 
premature death and complications which raised thousands of hospitalizations 
account for much of the social and financial burden of disease. 
2.2.1 Microvascular Complications 
2.2.1.1 Diabetic Retinopathy 
Diabetic retinopathy is the most frequent cause of new cases of blindness 
among adults aged 20-74 years. During the first two decades of disease, nearly 
all patients with type 1 diabetes and >60% of patients with type 2 diabetes have 
retinopathy. The prevalence between 1990 and 1996 for patients with newly 
diagnosed Type 2 DM has been estimated to be 22% in Hong Kong^i’ and a 




In addition, Peter C. Tong et al, from Hong Kong found that the presence of 
retinopathy was the second best predictor of composite endpoints (death, 
cardiovascular events, and end-stage renal disease (RR 1.70 [1.40-2.07]) after 
the preexistence of cardiovascular disease. The RR increased from 2.8 in 
patients with 1 risk factor to a relative risk of 44.8，when all 6 risk factors were 
present. These data clearly indicate the prognostic value of diabetic 
retinopathy in cardiovascular morbidity in Type 2 DM)? 
The protective effect of glycemic control has also been for confirmed patients 
with type 2 diabetes. The U.K. Prospective Diabetes Study (UKPDS) 
demonstrated that improved blood glucose control reduced the risk of 
developing retinopathy and nephropathy and possibly reduces neuropathy. The 
overall rate of microvascular complications was decreased by 25% in patients 
receiving intensive therapy versus conventional therapy. Epidemiological 
analysis of the UKPDS data showed a continuous relationship between the risk 
of microvascular complications and glycemia, such that for every percentage 
point decrease in HbAic (e.g., from 8 to 7%), there was a 35% reduction in the 
risk of microvascular complications. 
The UKPDS also investigated the influence of tight blood pressure control*^. A 
total of 1,148 hypertensive patients with type 2 diabetes were randomized to 
less tight (<180/105 mmHg) and tight blood pressure control (<150/85 mmHg) 
with the use of an ACE inhibitor or a B-blocker. With a median follow-up of 8.4 
years, patients assigned to tight control had a 34% reduction in progression of 
retinopathy and a 47% reduced risk of deterioration in visual acuity of three 




there were reductions in deaths related to diabetes and strokes. 
* 
2.2.1.2 Diabetic Nephropathy 
Diabetic nephropathy develops in approximately 15 — 60% of patients with 
type 2 diabeteses. It is the leading cause of end-stage renal disease (ESRD) in 
the United Status, Europe, Latin America and Asians and is responsible for 
about one third of patients who undergo dialysis"^^. In the U.S., diabetic 
nephropathy accounts for about 40% of new cases of ESRD, and in 1997，the 
cost for treatment of diabetic patients with ESRD was in excess of $15.6 billion. 
In Hong Kong, over 50% of diabetic patients have coexisting hypertension, 
dyslipidemia and/or abnormal albuminuria. Furthermore, up to 30% of Hong 
Kong patients on long-term renal replacement therapy have diabetes/^'"^^ 
Clinically diabetic nephropathy is defined as having persistent proteinuria (> 
0.5 g/d) or urinary albumin excretion (UAE) rates in excess of 200 |ig/min or 
300 mg/24 hr in the absence of urinary tract infection, other renal disease, or 
serious hear failure. Such macroalbuminuria is often associated with 
retinopathy and elevated blood pressure. Definitions of abnormalities in 




Table 6: Definitions of abnormalities in albumin excretion 
Spot collection 24-h collection Timed collection 
Category ()xg/mg creatinine) h) ( t ig/min) 
Normal < 3 0 < 3 0 < 2 0 
Microalbuminuria 3 0 - 2 9 9 30-2QQ 2 0 - 1 9 9 
Clinical a lbuminuria > 3 0 0 > 3 0 0 > 2 0 0 
Because of variability in urinary albumin excretion, two of three specimens collected within a 3- to 6-month 
period should be abnormal before considering a patient to have crossed one of these diagnostic thresholds. 
Exercise within 24 h, infection, fever, congestive heart failure, marked hyperglycemia, marked hypertension, 
pyuria，and hematuria may elevate urinary albumin excretion over baseline values. 
Microalbuminuria is an important parameter because of its potent predictive 
value. It is a major independent marker for macrovascular disease and early 
cardiovascular mortality. Around 20% of type 2 diabetic patients with 
microalbuminuria progress to overt proteinuria over a decade^s. 
Micralbuminuria in type 2 diabetes is multifactorial. Arterial pressure, blood 
glucose level, duration of diabetes, serum lipid concentrations, body mass 
index, baseline UAE rate and HbAlc have all been shown to correlate with the 
development of microalbuminuria.s. It has been reported that the prevalence 
rates of microalbuminuria in patients with Type 2 DM are between 8% and 
43% in Europeans and 26% in both Pima Indians and some Asian populations. 
48’ 51, 50 
2.2.1.3 Diabetic Neuropathy 




Studies suggest that up to 50% of people with diabetes are affected to some 
degree. Major risk factors of this condition are the level and duration of 
elevated blood glucose. Neuropathy can lead to sensory loss and damage to 
limbs. It is also a major cause of impotence in diabetic men. 
In the treatment of diabetic neuropathy, glycemic control must be optimized. 
The use of tricyclic antidepressant drugs and antiepileptic drugs may relieve 
symptoms of sensory neuropathy especially if hyperesthesia is present. 
2.2.1.4 Diabetic Foot 
Diabetic foot, due to changes in blood vessels and nerves, often lead to 
ulceration and subsequent limb amputation. It is one of the most costly 
complications of diabetes. It results from both vascular and neurological 
disease process. Sensory abnormalities, muscle weakness and wasting，foot 
deformity, peripheral vascular disease, automic vascular dysfunction, and 
increased susceptibility to infection are risk factors contributing to diabetic foot 
problems and manifesting as ulcers (neuropathic or ischemic), gangrene, and 
eventually leg amputation. 
In the United States, more than 50% of nontraumatic leg amputations are 
related to diabetes mellitus. The 4-year incidence of lower limb amputation 
ranges from 2% to 4% in diabetic patients. Over 60% of patients with lower 




2.2.2 Macrovascular Complications 
The risk of ischemic heart disease is 2-4 times greater in diabetes and 
particularly higher in women with diabetes. The results from a population-
based study suggest that there is a 10-fold increase in coronary artery disease 
among Chinese diabetic patients when compared with the characteristically low 
rate among non-diabetic controls.^' 
In people with diabetes, coronary heart disease (CHD) occurs at a younger age, 
and women are affected as often as men. In the Multiple Risk Factor 
Intervention Trial, the age-adjusted incidence of CHD was 4 times greater in 
people with diabetes than in those without diabetes.^^ The cardiac mortality in 
diabetes approaches 70%. In the Framingham Heart Study, HbAlc was related 
to the prevalence of CVD among older women but not men.^^ In the San 
Antonio Heart Study, cardiovascular mortality increased in people with type 2 
diabetes as FPG increased. In people with FPG < 8 mmol/L), the mortality was 
2.8 per 1000 person-years.^"^ This increased to 6.3 in people with FPG 8-11.5 
mmol/L and 11.6 in people with FPG > 11.5 mmol/L. Paradoxically, despite 
the relationship of heart disease to glucose levels, studies to control glucose 
have achieved little success in reducing cardiac events. In the United Kingdom 
Prospective Diabetes Study (UKPDS), the development of fatal or nonfatal MI 
had a non-significant, 16% relative risk reduction (P = .052). The effect was the 
same despite the initial therapy -- insulin or sulfonylurea ~ used to correct 
hyperglycemia.^^ In the UKPDS epidemiology study, for each 1% reduction in 




nonfatal stroke, and a 16% decrease in heart failure. ^^  These apparent 
contradictions illustrate that there are many potential mechanisms of increased 
cardiovascular damage in diabetes. These include hypertension and 
dyslipidemia. As a result, the National Diabetes Education Program (NDEP), 
an alliance between the National Institutes of Health and the Centers for 
Disease Control (CDC) in the Unities States, launched a public service 
campaign aiming at educating diabetic patients about cardiovascular risk, to 
know their "A, B, C", with "A" signifying HbAlc < 7%; "B" referring to blood 
pressure < 130 / 80 mmHg; and "C" representing low-density lipoprotein (LDL) 
cholesterol level < 100 mg/dl. 
Cardiovascular disease accounts for most cases of diabetic macrovascular 
complications; the remainder are caused by cerebrovascular events and 
peripheral vascular disease" 
2.3 Type 2 Diabetes Mellitus - A Rising Global Burden 
2.3.1 Prevalence of Type 2 Diabetes Mellitus 
The number of people with diabetes in the world is expected to approximately 
double between 2000 and 2030. The prevalence of diabetes for all age-groups 
worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total 
number of people with diabetes is projected to rise from 171 million in 2000 to 
366 million in 2030. Most of this increase will occur as a result of 150% rise 
in developing countries which was illustrated in Figure 6. The substantial 
growth is due to population growth, aging urbanization, and increasing * 
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prevalence of obesity and physical inactivity.^^ 
F i g u r e 6 : P r e v a l e n c e o f d i a b e t e s in t h e w o r l d " 
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The importance of age on the prevalence of diabetes was illustrated in Figure 7 
which showed sex-specific estimates of diabetes prevalence by age. Globally, 
diabetes prevalence is similar in men and women but it is slightly higher in men 
C Q 
< 60 years of age and in women at older ages. 
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Figure 7: Global diabetes prevalence by age and sex for 2000^® 
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In developing countries, the majority of people with diabetes are in the middle, 
productive years of age, i.e. 45- to 64-year. In these countries, three-quarters 
of all people with diabetes are under 65 years old and 25% of all adults with 
diabetes are younger than 44. In contrast, more than half of all people with 
diabetes in the developed countries are > 64 years of age, and only 8% of adults 





Figure 8: Estimated number of adults with diabetes by age-group, year and countries for the 
developed and developing categories and for the world�® 
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The 10 countries estimated to have the highest numbers of people with diabetes 
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in 2000 and 2030 are listed in Table 7. In 2000，there is 20.8 million of 
diabetes in China and this figure will be more than doubled to 42.3 millions by 
2030. China is the country with the second largest population of diabetic 
patients in the world. 
Table 7: List of countries with the highest numbers of estimated cases of diabetes for 2000 
and 203058 
2000 2030 
People with People with 
Ranking Country diabetes (millions) Coumiy diabetes (millions) 
1 India 31.7 India 79.4 
2 China 20.8 China 42.3 
3 U.S. 17.7 U.S. 30.3 
4 Indonesia 8.4 Indonesia 21,3 
5 Japan 6.8 Pakistan 13.9 
6 Pakistan 5.2 Brazil 11.3 
7 Russian Federation 4.6 Ban^adesh 11.1 
8 Brazil 4.6 Japan 8.9 
9 Italy 4.3 Philippines 7.8 
1 0 BangladeA ^ Egypt ^ 
2.3.2 Prevalence of Type 2 Diabetes Mellitus in Hong Kong 
In Hong Kong, diabetes mellitus is a growing public health problem and over 
97% of diabetes mellitus patients were considered to have Type 2 diabetes 
mell i tus60�The prevalence rate of diabetes is estimated to be 9.8% based on 
WHO 1998 criteria for people aged between 25 and It is one of the top 
five leading chronic health conditions for people aged over 60 and above as 
shown in Figure 9.62 
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Figure 9: Proportion of people aged 60 and above, by five leading types of chronic health 
condition, 2000’ Hong K o n g " 
Tvp* of chronic condition 
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Arthritis p H H H H H I H i P l H H H i j ^ l ^ H 
Diabetes nwUitus 2 0 .州 
I£gb cholesterol ^ H I H I H ^ H H 夏十州 
Note: Multiple answers were allowed. 
Source: Census and Statistics Department 2001. 
To date, several large-scale epidemiological studies have been performed in 
Hong Kong. In 1987, based on a household sampling method, the prevalence 
of diabetes was reported to be 9.8% in 427 Chinese subjects aged 60 years or 
above. This percentage increased to 17.1% in those over 75 years o l d " 
Similar prevalence rates have also been reported in another study involving 
1,467 ambulatory elderly subjects aged 60-90 years.64 In 1990, using the World 
Health Organization (WHO) criteria, the crude prevalence of diabetes was 
4.5% in a workforce of 1,513 subjects aged 30-65 years. Over 60% of these 
subjects were previously undiagnosed. The age-adjusted prevalence of 
diabetes was 9% in men and 6.3% in women.^^ In 1995, a population-based 
cross-sectional study, the Hong Kong Cardiovascular Risk Factor Prevalence 
Study, which involved 2900 Hong Kong Chinese aged 25-74 years using a 75-g 
oral glucose tolerance test (OGTT), showed the prevalence of Type 2 diabetes 
mellitus of 9.8% based on WHO 1998 criteria. It increased markedly with age 
to 29.3% in women and 21.7% in men who are 65-74 years old.^' This age 
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distribution is similar to that in the developed countries as shown in Figure 8. 
However, according to a recently published Population Health Survey 
2003/200466，the prevalence of diabetes is estimated to be only 3.8%. A 
further 97,800 (1.7%) persons have been told by a doctor or health professional 
that their blood sugar is high. The prevalence of diabetes increased from 
0.7% in persons aged 15-44 years to 4.8% in persons aged 45-64 years, and 






Figure 10: Prevalence of people having diabetes in Hong Kong 2003 (data source: Centre for 
Health Promotion, Department of Health, Hong Kong^^) 
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Such a big difference between the prevalence of Type 2 DM reported in the 
Population Health Survey 2003/2004 and the other epidemiological studies 
should be interpreted with care. The statistics presented in the Population 
Health Survey 2003/2004^^ is most likely an underestimation because diabetes 
may not be accurately reflected in hospital discharge records and death 
certificates. Besides, the true prevalence of diabetes or high blood sugar level 
in Hong Kong may again be underestimated as many people may have no 
symptoms and are not aware of having diabetes or high blood sugar. Thus, the 
author decided to use a conservative and clinical-based approach using the 
prevalence rate estimated by the Hong Kong Cardiovascular Risk Factor 
Prevalence Study, i.e. 9.8% for people aged between 25 and 74; and 21.7% for 
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people aged 75 and above (assuming the prevalence of diabetes for people aged 
75 and over is the same as that in men aged 65 - 74 years.) In mid 2004， 
population aged 25 and 74 was 4.6 million; and that aged over 75 was 0.3 
million; and of which about 95% of population was Chinese^^. Thus, about 
525,000 local residents which included both Chinese and non-Chinese; and 
499,000 Chinese residents out of a population of 6.8 million in 2004 were 
suffering from the disease. 
2.3.3 Mortality and Morbidity of Type 2 Diabetes Mellitus in Hong 
Kong 
2.3.3.1 Mortality of Type 2 DM in Hong Kong 
In contrast to Western countries where coronary arterial disease is the main 
cause of mortality in diabetic patients, renal failure and cerebrovascular 
accident are the leading cause of death among diabetic patients in Hong Kong 
Chinese.68’69 Cardiovascular, cerebrovascular and diabetes are the and 
8th leading causes of death in Hong Kong in 2003，respectively. In total, 9,554 
persons died from these three diseases in 2003 and 13% are in their working 
ages.70 The loss of productivity due to premature mortality, especially during 
the working age, can pose a significant economic impact to the society. 




death rate of diabetes per 100,000 population escalated from 0.3 in persons 
aged 14-44 years to 5.5 in persons aged 45-64 tears, and jumped substantially 
to 85.7 in persons aged 65 or above. As mentioned previously, it ranked as 
the eighth leading cause of death in Hong Kong. The number of death for 
which diabetes was certified as the underlying cause has increased by 36.4% 
from 574 in 2002 to 783 in 2003.66 
Table 8: Burden of illness due to diabetes, H o n g K o n g 2003^^ 
Age No. (rate") ofdeatiis [1] No. (rate*) ofia-patieut No. (rate*) of people haviag 
dischalf es and deaths m diabetes [3] 
^ ^ HAk»pitah[23 
Male Female Total Male Female Total Male Female Total 
Hor 0 0 0 « is l i NA ^ XA 
below (0.0) (0.0) (0.0) (8.0) (16-4) (12.1) 
15-44 5 6 i l Wi ^ T m 75« 14321 21SS3 
(0.3) (P3) (0.3) (50.2) (34.6) (41.9) (S45.tf) (825.8) QWU) 
" 4 5 ^ 51 15 90 rS? 40620 8 5 ^ 
<6.2) (4^) <5.5) (276.9) (210.1) C^.O) (5 042.1) (4 639.5) (4g32i) 
65 or ^ 682 3 ^  7812 47M2 5^ 438 106540 
above (级5) (SOT) (85.7) (947.g) (1011.5) (9S2.0) (12 530.0) (14 373.8) CB4S0.3) 
Tola： in 471 i i 7m ilw iTiw 96 oss 117721 213 餅 
(9.S) (13.4) (11.5) (20&.S) (IMP) (195.6) Q 723.8) (3 78S.S) (3 761.6) 
Notes: • Bzie per 100 OOC ixqwlaocm; NA meuis "Mot AvaiUbk" 
Source-【1】Mona% MatUtics’ 2003 (prwuional data). Depanaeat of Health, Census acd Statistics Deparenfui 
[2] to-patient stttUtics, 2<»3 (prwisioml daw). Hospital Author.n,'. 




Figure 11: Rate of deaths due to diabetes in Hong Kong 2003(data source: Centre for Health 
Promotion, Department of Health, Hong Kong 
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2.3.3.2 Morbidity of Type 2 DM in Hong Kong 
Thirty percent of patients admitted with stroke?'’ 72,73，21% admitted with 
heart failure?^，26% requiring renal dialysis?�，or 35% having retinopathy^^ 
have diabetes as a major contributing factor. Often, diabetes is diagnosed for 
the first time when it presents with these complications. A major concern is 
the high prevalence and severity of microvascular complications in many 
young diabetic patients/^ In 2003, diabetes was responsible for nearly 13,300 
in-patient discharges and deaths in Hospital Authority (HA) hospitals, in which 
•TO 
129 (1.0%) were among children aged 14 years or below. The in-patient 
discharges and deaths also rose drastically from 41.9 in persons aged 15-44 





Figure 12: Rate of in-patient discharges and deaths in Hospital Authority hospitals (public 
hospitals) in Hong Kong 2003 (data source: Centre for Health Promotion, Department of 
Health, Hong Kong'^') 
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Focusing the in-patient discharges in HA hospitals (public hospitals) only, the 
rate increased markedly by 3.8 times from 238.5 in persons aged 45-64 to 896.3 




Figure 13: Rate of in-patient discharges in Hospital Authority hospitals (public hospitals) in 
Hong Kong 2003 (data source: Centre for Health Promotion, Department of Health, Hong 
Kong 66) 
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Hence, the direct medical cost for diabetes due to its high complication rate 
nature is expected to be huge. However, till now no study has ever been 
published to explore its economic impact to our society. 
2.3.3.3 Ropulation and Age Structure Projection in Hong Kong 
Nevertheless, the burden of diabetes is expected to continue to rise in the next 
thirty years due to our expanding and aging population. According to the 
Hong Kong Population Projections 2004-2033^^, the population is estimated to 
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increase from 6.8 million in 2003 to 8.4 million in 2033. The proportion of 
persons aged over 65 years will rise by 1.3 times from 12% in 2003 to 27% in 
2033 as shown in Figure 14. The expectations of life at birth will also 
increase from 84.3 in 2003 to 88.0 in 2033 for women and from 78.6 in 2003 to 
82.5 for men (Figure 15). 
Figure 14: Hong Kong Population and Age Structure Projections^^ 
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Figure 15: Hong Kong Mortality Projections^^ 
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2.4 Cost of lype 2 Diabetes Mellitus 一 Under-explored Area in 
Hong Kong and Asia 
There is an increasing trend in the number of published economic evaluations 
of diabetes interventions as shown in Figure 16. In total, 301 articles were 
identified from the March 2000 version of the Health Economics Evaluations 
Database (HEED). However, most of the data were applicable to the USA 




Figure 16: An increasing trend in the number of published economic evaluations of diabetes 
interventions®® 
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Nevertheless, after searching the Medline database 1966 一 2004, no paper of 




found. Only two posters on burden of Type 2 DM in urban China^' and 
Australia were published at one scientific conference in 2003. Since every 
country has its own medical financing system; and the prevalence and 
complication rates of Type 2 DM is also different, there is a strong need to 
explore the economic impact of this costly disease to our society. 
2.4.1 Cost of Type 2 Diabetes Mellitus in the USA 
Although costs of diabetes in other countries may not be applicable to the local 
healthcare environment, we can take these cost data as references. 
Diabetes is the fifth leading cause of death by disease in the U.S. Diabetes also 
contributes to higher rates of morbidity; people with diabetes are at higher risk 
for heart disease, blindness, kidney failure, extremity amputations, and other 
chronic conditions. Several cost-of-illness studies were conducted in the USA 
from 1986 - 2002 to estimate the cost of diabetes mellitus. In 1986，the total 
economic burden of Type 2 DM, including health care expenditures and 
productivity forgone due to disability and premature mortality, was 19.8 
bi l l ion" This figure jumped markedly to 132 billion in 2002.84 cost 




Figure 18: Total Cost of diabetes in the USA, 2002 (data source: American Diabetes 
Association^'') 
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2.4.1.1 Direct Costs 
The per capita health care expenditures attributable to diabetes were 
US$10,071 in 199785, and US$13,243 in 2002. When discounting for 3% 
annually, the adjusted per capita health care expenditures was US$11,416 in 
2002, which represented a 13.4% increase in 5 years time. U.S. health 
expenditures for the health care components in 2002 totaled $865 billion, of 
which $160 billion (18.5%) was incurred by people with diabetes. 
Direct medical expenditures alone totaled $91.8 billion and comprised $23.2 
billion for diabetes care, $24.6 billion for chronic complications attributable to 




Inpatient days (44%), nursing home care (15%), and outpatient care (22%) 
constituted the major expenditure groups by service settings which are 
illustrated in Figure 19. 
Figure 19: Health care expenditures attributable to diabetes in the USA, 2002 (US$ millions) 
(data source: American Diabetes Association^'') 
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In addition, 51.8% of direct medical expenditures were incurred by people >65 
years old. Per capita medical expenditures totaled $13,243 for people with 
diabetes and $2,560 for people without diabetes. When adjusting for 
differences in age, sex, and race/ethnicity between the population with and 
without-diabetes, people with diabetes had medical expenditures that were 
about 2.4 times higher than expenditures that would be incurred by the same 




Table 9: Annual per capita health care expenditures by diabetes status in the USA, 2002^^ * 
Unadjuacd Adjusted* 
WUh Wuhom Ratio with to Withoul Ratio with to 
Co5i coroponcnt diabclcs thabctcs sv^ihom dubcic5 dubctcs vdihout dmbcies 
HaspusSinpaiient S�309 SI,289 4.9 S2.971 2.1 
Nursing home 2.140 247 8,7 991 2.2 
PhysicianVofFioc 1.525 4)0 l/i 糾 5 2.2 
Haspiu] outpacieni 489 154 3.2 215 2.3 
ETncrgcncy 366 163 2.2 187 iO 
Hcm« health 516 58 8.9 190 2.7 
Hospice ti4 11 7,9 3V> 2.1 
AmbuUnce service 23 9 2,ft 11 2 ] 
Outpattcm mcdication 797 202 3.9 Ml 2.3 
Insulin & dclivcr>- supplies 579 NA NA NA NA 
Oral agcnis 414 NA NA NA NA 
TocaJ health care costs 513,243 $2,560 S5.642 2.-* 
'Adjuwed lo re flea denvogrjipJhK c«nporaiimi <4 the populate with dubet«< 
Most of the health care use attributable to diabetes is for the treatment of 
general medical conditions, i.e., visits or inpatient days where the primary 
diagnosis is neither diabetes nor one of the seven chronic complications 
analyzed. For example, 63% of hospital inpatient days attributable to diabetes 
fall under the category of general medical conditions. Of the seven chronic 
complications analyzed, cardiovascular disease accounts for the largest 
proportion of health care use attributable to diabetes. For example, in 2002, an 
estimated 4 million hospital inpatient days were attributable to diabetes where 
the primary diagnosis is related to cardiovascular disease. This constitutes 24% 
of total hospital days attributable to diabetes and 19% of total U.S. inpatient 




Detailed event costs for different diabetes complications estimated by Judith A. 
O'Brien et al. in the USA are listed in Table 10. The estimates were based on 
precoded per-event costs derived from sources such as hospital discharge 




Table 10: Event and state costs of nonepisodic complications®^ 
COM 
Hveni cost Siaie cosi 
Complication ( 1暢 U.S.S) (U.S $ annuahzed) 
Cardiovascular 
2,185 
Angina 2.477 1,082 
Cerebrovascular 
Ischemic stroke 40,616 s),255 
TIA 6.204 45 
Nephropaihy 
Microalbuminuria 52 14 
Gross proicinuna 6Q 
ESRD � ” 53�(^59 
Retinopathy 
Background retinopathy 0牛 57 
Macular edema 1,100 57 
Proliferative diabcuc retinopathy 1,044 57 
Blindness ‘ 3,486 
Neuropathy 
Sympioniaiic ncuropathy 218 一t 
1st LEA ‘ 26.894 1.73^ 
2nd LEA 27,\M —^ 
*Eveni co!>is were noi calciilaicd scparaicly lor HSRD as ilu-y are included in ihc composiic siaic cosi 
lexi), tlnsuiftaem data available to csiimaic cosi uscf text), ？No Jireu cosis .irc .lunbuuhle to ihis condi-
non as an ovcni (stc lexi) 
Note: 
All event cost estimates both acute care (initial management in an inpatient or outpatient setting) 
and subsequent care rendered in the year. Subsequent care may comprise subacute 
inpatient care (i.e. rehabilitation hospitals, skilled nursing facilities, intermediate care nursing 
facilities, chronic disease hospitals), home health care, outpatient therapy, physician visits, and 
diagnostic and therapeutic procedures depending on the complications addressed. 
State costs reflect annual resource use required beyond the year for the ongoing management 
of the given health state and would apply while that particular health state is present for the 




However, when different methodology and sources of data were used, the event 
costs varied a lot. Brown et al evaluated the costs of diabetes arouse from 
treating cardiovascular and renal complications on 11,768 members of a large, 
not-for-profit, group model health care management organization (HMO) using 
costs identified from aggregate departmental expenditures rather than from 
procedure-specific charges or prices. The event costs were much lower. 
Per-person costs increased over baseline ($2033) by more than 50% ($1087) 
after initiation of cardiovascular drug therapy and/or use of a cardiologist, and 
by 360% ($7352) after a major cardiovascular event. Abnormal renal function 
increased diabetes treatment costs by 65% ($1337); advanced renal disease, by 
195% ($3979); and end-stage renal disease, by 771% ($15,675).^'' These are 




Figure 20: Effect of two major complications on the average cost per Type 2 DM patient in 
one US not-for-profit HMO (US$, 1993 values) (data source: Brown, Jonathan B. et al.") 
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2.5.1.2 Indirect Costs 
Attributable indirect expenditures resulting from lost workdays, restricted 
activity days, mortality, and permanent disability due to diabetes totaled $39.8 
billion in the USA in 2002，which contributed 30% of the total cost of diabetes. 
The cost components attributable are illustrated in Figure 21. 
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Figure 21: Indirect costs due to lost productivity in the USA, 2002 (data source: American 
Diabetes Association 8” 
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In a national self-reported population survey for persons aged between 18 and 
65 years in the USA in 1989, Ng et al. reported that the presence of diabetes 
reduced employment by 3.5%, and the presence of complications reduced 
employment by 12% compared with the absence of complications. For those 
individuals who were employed, having diabetes did not have a significant 
overall effect on hours worked, however, those had complications worked 83.2 
days fewer per year than whose diabetes were without complications. In 
general, the loss of yearly earnings amounted to about a one-third reduction in 
earnings and ranged from $3700 to $8700 (1989 US dollar) per annum.88 
When claims data in 1998 for a large employer population were analyzed, the 
mean duration of a disability claim was doubled for diabetic employees (41 士 
98 days), versus those without diabetes (22 土 73 days). The mean annual 




days for diabetic employees versus 5 土 11 days for control subjects. ^^  
Diabetes imposes a significant economic burden on the employer, as well as the 
society in the USA. 
2.4.2 Cost of Type 2 Diabetes Mellitus in Europe 
CODE-2 study, "The Cost of Diabetes in Europe — Type II” is the first 
coordinated attempt to measure the total healthcare cost of Type 2 DM in 
Europe. The study evaluated more than 7000 patients with Type 2 DM in 
eight countries - Belgium, France, Germany, Italy, the Netherlands, Spain, 
Sweden and the United Kingdom. A bottom-up, prevalence based design was 
usecl.90 
2.4.2.1 Direct Costs 
The total direct medical cost of Type 2 DM in the eight Europe countries was 
estimated at EUR 29 billion a year (1999 values). The estimated average 
yearly cost per patient was EUR 2834 a year (Table 11). Of these costs, 
hospitalizations accounted for the greatest proportion (55%, range 30-65%) 
totaling EUR 15.9 billion for the eight countries as illustrated in Figure 22. 
During the 6-month evaluation period, 13% of the Type 2 DM patients were 
hospitalized, with an average of 23 days in hospital projected annually. In 
contrast, drug costs for managing Type 2 DM were relatively low, with 
antidiabetic drugs and insulin accounting for only 7% of the total healthcare 
costs for Type 2 DM. When the components of the total drug cost category • 
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were considered in isolation, cardiovascular and lipid-lowering agents 
represented the largest proportion (42%) with oral antidiabetic drugs 
accounting for only 13% and insulin 11% of total drug costs as shown in Figure 
22.91 
Table 11: Yearly direct medical costs for Type 2 DM pts in the CODE-2 study (Euro, 1999 
values)^' 
Country Ibtal cost per Total p«-patiMit cost m Percent of total healthcare 
country (Euros) Euros M e ^ ± SD (range) expenditures in each country* 
Belgium 1,093,625,291 3295 ± 6550 N/A 
(40-73885) 
France 3,983,000,000 3064 ±6696 3.4 
(20-32630) 
Germany 1.243,745.000 3576 ± 920 6.5 
(80-70131) 
Italy 5,170,025,166 2991 ±9059 6.6 
(23-81447) 
Netherlands 443,915.000 1827 ± 44S5 1.6 
(29-^7727) 
Spain 1,957,735,697 1305 ± 2197 N/A 
(16-27665) 
Sweden 736.000.000 2630 ±6630 N/A 
(7-35620) 
UK 2,607,799,104 2214 ± 3643 2.5 
(25-50W7) 
Total CODE-2 avwage 28.429,336.630 2834 





Figure 22: Distribution of direct medical costs for Type 2 DM patients in the CODE-2 study^' 
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Complications have a substantial impact on the costs of managing Type 2 DM 
patients. 72% of patients in the CODE-2 study had at least one complications, 
with 19% having microvascular only, 10% having macrovascular only and 24% 
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of the total having both microvascular and macrovascular complications. In 
patients with both microvascular and macrovascular complications, the total 
cost of management was increased by up to 250% compared to those without 
complications as shown in Figure 24 and Figure 25. 
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Figure 25: Effect of complications on hospitalization costs in the CODE-2 study'' 
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2.4.3 Cost of Type 2 Diabetes Mellitus in Asia-Pacific 
As mentioned previously, cost-of-illness for Type 2 DM is an under-developed 
area in Asia-Pacific. No paper of cost of Type 2 diabetes mellitus for the 
Asia-Pacific region was found after searching the Medline database 1966 — 
2004. Only two posters on burden of Type 2 DM in urban China^^ and 
Australia^^ were published at one scientific conference in 2003. 
2.4.3.1 Direct Costs in Urban China 
In urban China, the total cost of Type 2 DM was estimated to be US$ 2.8 
billion in 2001 in which 89% was the direct costs. The total medical cost of 
treating Type 2 DM was US$2.3 billion, which was about 3.9% of the total 
healthcare expenditure of China in 2001. The annual direct medical cost per 
patient was US$450 for treating uncomplicated Type 2 DM patients and 
US$1,673 for managing complicated patients. The direct medical cost of 
treating a patient with complications was 3.7 times higher than that of treating 
an uncomplicated patient. However, for patients with both microvascular and 
macrovascular complications, the direct medical cost increased to 10.4 times 
higher than treating those without complication as illustrated in Figure 26. 
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Table 12: Impact of complications per patient on the costs of Type 2 DM in urban China 
(US$, 2001 values)' ' 
Complication category Cost (US$, 2001 values) 
Direct medical Direct non- Indirect Annual Total 
medical 
Without complication 450.6 74.5 52.4 577.2 
Microvascular 1431.9 187.2 207.0 1826.1 
Macrovascular 1859.0 217.3 201.4 2277.7 
Macrovascular + Microvascular 4665.1 236.9 474.7 5376.7 
Figure 26: Impact of different complication per patient on direct medical cost of Type 2 DM in 
urban China (US$, 2001 values) (data source: Chen Xingbao et a l ? ) 
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2.4.3.2 Cost of Type 2 DM in Australia 
Diabetes is associated with significant morbidity and premature mortality. 
The prevalence of diabetes in Australia is 7.4% and is increasing.^'^ Type 2 
DM impacts significantly on affected individuals and their carers in Australia. 
The onset of macrovascular and microvascular complications increases the 
burden of illness through deterioration in quality of life and increased costs to 
the community. The DiabCost study, which involved 25,000 people with Type 
2 DM, was carried out to examine the burden of this disease in Australia. The 
overall cost of Type 2 DM in Australia was found to be in excess of A$3 billion 
in which 70% was the direct costs and 30% was the indirect costs.^^ This 
represented over 5% of Australia's healthcare expenditure and nearly 0.5% of 
gross domestic product. 
I 
In the DiabCost study, 66.8% of Type 2 DM patients has no complication, 
22.5% has microvascular complication, 2.0% has macrovascular complication, 
and 8.7% has both microvascular and macrovascular complication. The 
greater the number of complications, the higher the average costs as shown in 
Table 13 and Figure 27. 
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Table 13: Total patient costs by complication in the DiabCost study of Australia (data source: 
Davey P. et al. 
Cost (A$) 
Direct medical Direct non- Indirect Annual Total 
Complication category medical 
Without complication 3335 655 35 4025 
Microvascular 5415 1575 35 7025 
Macrovascular 7250 1735 70 9055 




Figure 27: Total patient costs by complication in the DiabCost study of Australia®^ 
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2.5 Hong Kong Healthcare System 
Hong Kong has a unique health care system. Unlike many other countries, 
our health care services, especially the secondary and tertiary ones, are 
dominated by public hospitals or clinics, as shown in Figure 28. Over 93% of 
the secondary and tertiary healthcare services are provided by a government-
subsidized, not-for-profit, organization, the Hospital Authority.^^ 
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2.5.1 Hospital Authority in Hong Kong (Public Healthcare Sector) 
2.5,1.2 Hospital Authority - Background 
The Hospital Authority (HA) is a statutory body established on 1 December 
1990 under the Hospital Authority Ordinance to manage all public hospitals in 
Hong Kong. It is responsible to provide comprehensive preventive, curative 
and rehabilitative medical services to the people of Hong Kong. It is a 
government subsidized, not-for-profit, organization which receives 97% of its 
funding from the Government under a population-based funding arrangement. 
The remaining 3% of income comes from fees and charges that are set at a 
highly subsidized rate for Hong Kong residents, together with a waiving 
mechanism for the poor. Hence, it acts as the healthcare service provider, as 
well as the payer in Hong Kong. 
The Hospital Authority currently manages a Head Office，42 public hospitals / 
institutions and a host of ambulatory care facilities, including 47 specialist 
outpatient clinics and 72 general outpatient clinics. As of 2003, it also managed 
a total of 29,188 hospital beds, which represented around 4.2 public hospital 
beds per 1，000 population and 89% of total hospital beds in Hong Kong. In 
addition, there has been continuous growth in HA activities. Increases were 
recorded in total inpatient and day patient discharges and deaths, total general 
outpatient attendances and total specialist outpatient attendances. The growth 
rate of the total general outpatient attendances in 2002/03 was much higher 
than that of the previous years, while the total accident and emergency * 
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attendances, which had been on the increase over the past years, decreased in 
2002/03 as shown in Figure 29. 
Figure 29: Growth in Hospital Authority services'^ 
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2.5.1.2 Hospital Authority - Finance 
For 2003/04, the Hospital Authority received over 94% of its funding from the 
government. Its recurrent expenditure budget from Government, net of 
income, was reported to be HK$30,039 million with HK$32,232 million as the 
total recurrent expenditure. Moreover, it continued to have deficit since 2002. 
In 2003/4, the deficit rises to as much as HK$374 million as shown in Table 14. 
« 
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Table 14: Hospital Authority financial highlights 2002 - 2004^^ 
2001 2003 2002 
Financial Results ( for the Year ended 31 March) HK$Mn HKJMn HK$Mn 
財政情況(敏至海年3月31日) 港稱?{«元 港Ifmff元 itrffs元 
Income收入 
• GovBrnment subvenUon (recurrent and capital) 30.039 29.977 30,138 
政府_助（經常性及资本性> 
• MedJcal fee Income (net of walveri) 1.243 849 782 
B療費用收入（扣除R免） 
• Non-medical fee Income 294 321 361 
本8费R用收人 
• Designated donations 209 100 lOG 
担定招贈 
• Capital donations 73 78 87 
资本招明 ； 
31.858 31.325 31.474 
Fxpendiliirc 支出 
• Staff cojti (25.170) (24.798) (25.072) 
日工成本 
• Medical juppUes and equipment (2.797) (2.600) (2.570) 
fiSF物品及設備 
• Other operating expenses (include depredaUon) (4.265) (4.147) (4.093) 
其他營逋两支（包沾折in 
(32.232) (31.545) (31.735) 
Defici丨 for 丨丨ic Ywir 躬抿 (374) (220) (261) 
Total Expenditure 
總支出 
50% I ~ I Other operating 
0% SmBBBBmSsSB^^BSSIB^^BtKMtB^ 
- 2 0 0 1 2 0 0 3 2 0 0 2 
Year年份 
The huge expenditure of the Hospital Authority may be partly explained by its 
costing system. The fees and charges of the services provided by the HA are 
‘ 7 0 
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very low as listed in Table 15. According to the costs reported by the HA 
for 2003/04, HA is subsidizing 78 - 97% of healthcare services provided as 
shown in Table 16. 
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Table 15: Major fees and charges for public hospital services in Hong Kong'^ 
$100 per attendance 
毎次珍症 100 元 
$50 admission fee for the first day 
$100 per day 
k I I I I I I ^ H ^ ^ ^ ^ H 入院费 50元 
毎天 100 元 
^ n ^ ^ ^ ^ ^ H H H j j l ^ ^ ^ ^ H per day 
^ B S S ^ p S ^ g p S ^ ^ f f l ^ ^ H 每天 68 元 
^ ^ ^ ^ ^ K j j Q g ^ S n ^ ^ l ^ l ^ H $100 for the first attendance 





$45 per attendance 
毎次 45 元 
^ B i n B f f l w f l f f i i n f f f f i p ^ ^ ^ ^ ^ ^ M $55 per attendance 
毎次 55元 
per 
^ g l P m i l l ^ ^ ^ ^ ^ l 毎次 80 元 
^ • ^ ^ O f f i l f f i l t S i B B r B ^ I W f f l ^ B $64 per treatment 
^ ^ g P g J I I I I I I I I I I I l i m 毎次 64 元 
As at May 2004 截至2004無月 
Notes: 
• Seivicea are charged as per Gazette. Patients who have fbianclal difficulties can apply for 
waiver of fees. 
• Private services and non-ellglble persons w«l be chared full cost or market rates. 
Eligible persons of public health seruloes are hotders of Hong Kong Identity Card issued 






‘ 7 2 
» 
Chapter 2 
Table 16: Healthcare service subsidizing rate by the Hospital Authority in 2003/04 
HA Cost in HA Charge in HA Subsidizing 
Health Service 2003/04 (HK$)' 2003/04 (HK$) % 
General acute inpatient per dayb 3267 97 
Infirmary inpatient per day^ ^ 93 
Mentally ill inpatient per dayb ^ ^ 2 1 
Mentally handicapped inpatient per dayb 1171 ^ 94 
Accident and emergency attendence ^ 88 
Specialist outpatient attendance ^ 88 
Outreach service by community nurse ^ 78 
Psychiatric outreach attendance 1110 ^ 93 
Geriatric day hospital attendance 1910 : ^ 97 
Psychiatric day hospital attendance 990 ^ 94 
Note: 
'Source: Hospital Authority Annual Report 2003/04 
''calculated from cost per inpatient discharged divided by average of length of stays 
2.5.2 Hong Kong Healthcare Financing System 
Compared with other developed countries, the health service expenditure of 
Hong Kong is relatively low. It only contributes about 5.2% of our gross 
domestic product in 2003 as illustrated in Figure 30. 
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Figure 30: Hong Kong health services expenditure as percentage of gross domestic product^^ 
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The healthcare expenditure is the third leading expenditure of our government 
as shown in Figure 31. It is estimated that it will contribute 11.5% of the total 
government expenditure in 2004/05. In addition, it is reported that the 
healthcare expenditures continue to rise dramatically in the past decades. In 
2002, the government healthcare expenditure increased to HK$33,901 million 




Figure 31: 2004/05 Hong Kong Government public expenditure on health'， 
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Figure 32: Medical and Healthcare expenditure in Hong Kong 1987-2002^^ 
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2.6 New Emerging Drug Treatment for Type 2 DM in Hong 
Kong Chinese 一 Rosiglitazone 
2.6.1 Clinical Efficacy and Tolerability of Rosiglitazone 
Type 2 DM is characterized by insulin resistance as well as progress pancreatic 
p cell dysfunction. The cornerstone of current oral blood-glucose lowering 
therapy consists of metformin (MET), which primarily lowers hepatic glucose 
production, and the sulphonylureas (SU) that act by stimulating pancreatic p-
cell to secret insulin. Recently, a novel class of agents, the thiazolidinediones 
(TZD), has been introduced that favorably influence insulin sensitivity and 
possibly also pancreatic p-cell function. Two representatives of 
thiazolidinediones class, rosiglitazone and pioglitazone, have been available in 
the US, Europe, as well as Hong Kong, since 1999 and becomes widely 
prescribed nowadays. When given as monotherapy or in combination with 
sulphonylureas, metformin or insulin in patients with Type 2 DM, both of them 
ameliorate glycemic control by lowering fasting and postprandial blood glucose 
as well as circulating insulin levels. In addition, they lower HbAic values by 
1-2%，which is comparable to the effectiveness of metformin and 
s u l p h o n y l u r e a s . 9 7 The adverse events of both agents that occur with greater 
frequency than in patients treated with placebo are fluid retention, edema, 
QO 
weight gain and elevation of LDL cholesterol. 
Rosiglitazone, a member of the thiazolidinediones, has shown significantly -
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efficacy and was well tolerated in clinical trials of various ethnic groups, 
including Chinese. Yang J et al. showed that combination treatment of 
rosiglitazone and sulphonylurea can effectively improve glycemic control in 
Type 2 DM Chinese patients inadequately controlled with sulphonylurea 
a l o n e . 9 9 In addition, Zhu XX et al. proved that rosiglitazone plus SU was 
effective in reducing HbAlc and FPG levels and this combination was well 
tolerated irrespective of hepatitis B and C serological status.�^ 
Although the working mechanism of thiazolidinediones as a concept is 
appealing, and their effects in short-term clinical studies are promising, their 
efficacy and safety have not been demonstrated in any long-term outcomes 
studies yet. At present, several large-scale trials, like RECORD 
and PROACTIVE, are ongoing, which are going to address these issues. 
2.6.2 Cost-effectiveness of Rosiglitazone 
Cost-effectiveness of TZD has been demonstrated in one observation study in a 
group of low-income Type 2 DM patients enrolled in the North Carolina 
Medicaid Program in the USA who were newly started on TZD or other oral 
antidiabetics (i.e. SU or MET). It was shown that introduction of TZD was 
associated with significantly improved treatment adherence, persistence, and 
lower annual health care costs in the post-start year compared to patients 
starting other antidiabetics. These findings held, even when rosiglitazone or 
pioglitazone, were compared individually to sulphonylureas and metformin. 
However, there was no difference between the two TZDs.^^^ 
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In a literature based, decision-tree cohort model of projected efficacy (HbAlc 
<7% and direct costs (payer perspective) over 3 years, the short-term costs 
associated with rosiglitazone were higher than those for glipizide, metformin, 
glibenclamide/metformin, but less than those for repaglinide.'^^ However, an 
abstract reporting another pharmacoeconomic model of rosiglitazone in patients 
with Type 2 diabetes mellitus suggests that this drug appears to be a cost-
effective alternative to conventional therapies such as glibenclamide and 
metformin, despite higher associated costs with r o s i g l i t a z o n e . � ^ However, all 
of these cost-effectiveness analyses were conducted, and thus only applicable in 
the USA. None of these cost studies can be applied in Hong Kong. 
According to the expert opinion, the most commonly prescribed line 
antidiabetic agent in Hong Kong is metformin, especially in overweight Type 2 
DM patients. It may be due to the acceptance of a cost-effectiveness analysis 
of intensive blood-glucose control with metformin in overweight Type 2 DM 
patients (i.e. UKPDS No. 51 study). This study showed that the reduction in 
the costs of treating the complications of diabetes offsets the additional costs of 
therapy which resulted in an overall net s a v i n g . H o w e v e r , the UKPDS also 
demonstrated after 3 years, only 50% of type 2 DM was adequately controlled 
with a single antidiabetic agent, and after 9 years, this percentage had decreased 
to 250/0IO6. Is addition of which antidiabetic agent, SU or TZD more cost-
effective, after treatment failure of metformin? Till now, no clinical studies 
were published to address this question. As a result, we are going to develop 
a decision-analytic model, using a Markov process, to compare the cost-
effectiveness of Metformin and Rosiglitazone (M+R) vs. Metformin and 
Glibenclamide (M+R) in Type 2 DM HK Chinese patients whose diabetes * 
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cannot be adequately controlled by maximum dose of metformin alone, in order 




Chapter 3. Hypothesis and Objectives 
3.1 Cost of Type 2 Diabetes Mellitus in Hong Kong Chinese 
3.1.1 Hypothesis 
It was hypothesized the cost of Type 2 DM imposes a significant financial 
impact to the local healthcare system. The aim of this study is to examine this 
hypothesis. 
3.1.2 Objectives 
The primary objectives are: 
> To evaluate the cost of Type 2 DM and the proportion of burden of Type 2 
DM shared by our government (direct medical costs incurred at the HA), 
patient (patient's out-of-pocket expense) and the society (total cost, 
including indirect costs, e.g. loss in productivity) in a group of Hong Kong 
Chinese patients attending a government hospital from a societal 
perspective. 
> To identify major cost drivers for Type 2 DM HK Chinese patients in a 





The secondary objective is: 
> To estimate the economic impacts of Type 2 DM to local and 
government's healthcare expenditures. 
3.2 Cost-effectiveness Analysis of Metformin + Rosiglitazone vs. 
Metformin + Glibenclamide for Type 2 DM Patient Whose 
Diabetes is not Adequately Controlled by Metformin Alone from 
a Payer's Perspective 
3.2.1 Hypothesis 
Combination therapy of metformin (M) and rosiglitazone (R) was suspected to 
be more cost-effective in short-term (2-year period) than that of metformin and 
glibenclamide (G) in Type 2 DM patients whose diabetes is not adequately 
controlled by metformin alone. A decision-analytic model from a payer's 




The objective is to evaluate, using a decision analysis model, the short-term (2-
year period) cost-effectiveness of Rosiglitazone-based combination therapy (i.e. 
Metformin + Rosiglitazone) compared with the most commonly used 
alternative therapy (i.e. Metformin + Glibenclamide) for the treatment of Type 
2 DM patients whose diabetes is not adequately controlled by metformin alone, 
with the aim of informing decision makers in payer's (i.e. the Hospital 
Authority - the HK Government) perspective. 
In our systemic framework, patients who do not achieve glycemic control on 
one oral agent move to second-line therapy, which involves a combination of 
two or more antidiabetic agents, with or without insulin. Most patients with 
Type 2 DM will require multiple agents to achieve the recommended glycemic 
goals set forth by the American Diabetes Association (ADA). However, 
"what will be the most cost-effective antidiabetic agent to be an add-on for 
patients whose diabetes is poorly controlled by metformin alone, assuming the 
plan intends to treat all patients to achieve the recommended glycemic goals?" 




Chapter 4. Cost of Type 2 Diabetes Mellitus in Hong 
Kong Chinese 
4.1 Subjects and Methods 
4.1.1 Subjects 
This was a retrospective observational, prevalence-based study from a societal 
perspective carried out in one large, regional, acute general public hospital (i.e. 
United Christian Hospital) with 1,174 beds in Hong Kong. This hospital 
served over 562,472 Hong Kong residents with 14.5% of residents' age over 65 
years in 2001.�7 it is the single area in Hong Kong with the largest number of 
the elderly. The prevalence of Type 2 DM is especially high in the elderly. The 
author selected this hospital to conduct this study as the sample population 
would be representative; and the author could then generalize the results in 
order to estimate the cost of Type 2 DM in Hong Kong Chinese. 
The sample size of the study was calculated based on the large sample z 
statistic. The power was set to be 95% (2-sided) and confidence interval for a 
single mean was set to be 95% (2-sided). The single mean would extend 
HK$150 from the observed mean (i.e. HK$300 when 2-sided), assuming the 
standard deviation was HK$880 which was obtained from a published paper 
describing the medical care cost of T2DM in one not-for-profit Healthcare 
1 Qg 





assuming the response rate is 70%, approximately 190 patients would be 
needed for the study. 
Systemic sampling method was used in this study. Type 2 DM patients were 
identified from the electronic database of the hospital, namely the "Clinical 
Management System". Those having "2" or “4” or “6” as the first digit of 
their Hong Kong Identity Card (HKID) number who attended the diabetes 
specialist outpatient clinic of the hospital every Wednesday (for mild or stable 
cases) and Thursday (for moderate to severe cases) from Jan 2004 were 
selected and invited to complete a face-to-face interview by one well-trained 
study co-coordinator until the target number of subjects were enrolled. All 
patients would be interviewed once only in order to avoid double counting. If 
there were no Wednesday and/or Thursday DM clinic in a particular week, the 
enrollment in that week would be cancelled, in order to let the author have a 
balanced view of cases with different severity. This sampling method was used 
due to convenience and little selection bias. The first digit of the HKID 
number has no special meaning making this systemic sampling method similar 
to random sampling. In addition, time was saved as the subjects could be 
easily selected from the hospital database. 
4.1.2 Methods 
The author designed an excel spreadsheet to collect subjects' demographic data, 
such as gender, age, age at diagnosis of diabetes and co-morbidities, etc, and 
data required for calculating direct medical costs incurred at the United 
Christian Hospital, from the electronic database of the hospital, namely the 
85 
Chapter 2 
"Clinical Management System". In this system, a "DM Clinic Module" was 
specifically designed by the Hospital Authority to record the data of the DM 
patients, so the author would collect the data from this module of the system. 
All data collected were the past one year data from the time of interview of 
every subject which included subjects' characteristics, co morbidities, 
complications, number and type of ambulatory services used, number, duration 
and reason of hospitalization stays, number of day hospital stays, type and costs 
of medications the subjects took, number and type of laboratory tests the 
subjects required, etc. Details were listed below: 
Subject characteristics: 
Subject characteristics included age, sex, and duration of Type 2 DM since 
diagnosed, body mass index and waist-hip ratio and smoking status. 
Co morbidity: 
Co morbid diseases included hypertension, obesity, dyslipidaemia, and risk of 
foot problems. 
Complications: 
Complications included retinopathy, nephropathy (microvascular 
complications), coronary heart disease, stroke and peripheral vascular disease 
(macrovascular complications). 
Ambulatory services: 
Ambulatory services included specialist outpatient clinic visits, allied health 





dressing visits, and accident and emergency department visits. 
Hospitalizations: 
Hospitalizations included in-patients at the general ward, intensive care units 
and high dependency units. 
The other direct medical costs incurred outside the United Christian Hospital, 
(e.g. private practitioner's visit, Chinese practitioner's visit, hospitalization at 
private hospital, consumables, etc), and direct non-medical (traveling and 
special food costs) and indirect costs were collected using a Chinese 
questionnaire, namely ”香港第二類型糖尿病患者支出調查” developed by 
the author as shown in Appendix. During the development process, several 
drafts were created by the author and were reviewed by the author's supervisor. 
A pilot study was also run in a sample of 35 pts in Dec 2003. Modifications 
of the questions were done based on results of the pilot study. At last, a final 
survey was developed in Jan 2004. 
There were four dimensions in the survey: 
1. medical costs incurred outside the Hospital, i.e. frequency of visits to 
private practioners, private hospitals, Chinese Medicine practioners, 
private nutritionists; costs of consumables, etc 
2. other direct costs, e.g. costs of special food, traveling, etc. 





loss / reduction in productivity of their carers, etc. 
4. socio-demographics of the subjects, e.g. marital status, education level, 
insurance coverage, etc. 
Appropriate questions were then derived based on the above four dimensions. 
The Ethics Committee of the hospital approved the study and all subjects were 
asked to sign informed consent forms before the study started. 
4.1.2.1 Costs Calculation 
4.1.2.1.1 Direct Medical Costs Incurred at the Government Hospital 
It is the Hospital Authority's policy that non-eligible persons (i.e. non Hong 
Kong citizens) will be charged on a cost recovery basis, so we decided to use 
the unit costs of every type healthcare services published in the 2003 HKSAR 
Government G a z e t t e f o r the non-eligible persons as shown in Table 17 and 





Table 17: Sources of data for diabetes resources utilization and expenditure estimates in Hong 
Kong 
Non-Eligible Persons - Unit Price 
；• - •' . ‘ . 
； Type of Service per Attendance (HK$) 
Medical Services Provided by the Hospital Authority (Public Healthcare Sector)® 
General ward 3300 
Intensive care ward 13900 
High dependency ward 9800 
Accident and Emergency department 570 
General clinic 215 
Specialist clinic 700 
Allied health clinic 700 
Injection and dressing 70 
Community nursing services 340 





Blood cholesterol and triglycerides test 200 
Blood glucose test 100 
Liver function test profile (alkaline phosphatase, 100 
bilirubin (total), alanine aminotransferase (serum 
glutamate pyruvate transaminase) ALT (SGPT), 
total protein and albumin) 
Renal function test profile (creatinine, potassium, 100 
sodium and urea) 
Urine protein test 100 
Complete blood count test 120 
HbAlc test 300 
Loss / Reduction in Productivity 
Average daily wages (for employees up to 436 
supervisory Level, excluding managerial and 
professional Employees) ^ 
Average monthly wages (for employees up to 10459 







a Source of Utilization Data: Hong Kong Special Administrative Region Government S. S. No. 
4 to Gazette No. 13/2003 
b Calculated from Quarterly Report on General Household Survey, January to March 2004, 
Hong Kong Census and Statistics Department website 
It should be noted that the inpatient charges includes costs for clinical, 
biochemical and pathological investigations (including consultation, diagnostic 
imaging and other examinations), vaccines and general nursing, where such 
examinations or treatments are necessary, and prescriptions within the scale 
provided at the hospital and clinics. Similarly, the outpatient charges include 
the costs of prescriptions, pathology investigations, radiology and other 
examinations already. 
Then, the costs would be calculated by the following formula: 
Annual government direct medical costs 
=no. of clinic visits (or, days of hospitalization) per year x unit costs published 
in the Gazette 
4.1.2.1.2 Other Direct Medical and non-medical Costs Paid by the Subject 
The other direct medical and non-medical costs incurred outside the Hospital 




Annual patient out-of-pocket direct medical costs 
=no. of clinic visits (or, days of hospitalization) per year x unit costs reported 
by the subject via the interview 
This included costs of private practitioner visits, Chinese practitioner visits, 
private inpatient hospitalizations, private A&E visits and consumables. 
Annual other direct non-medical costs 
=costs reported by the subject via the interview 
This included traveling costs and special food costs. 
Hence, 
Annual total direct medical costs 
=Annual government direct medical costs + Annual patient out-of-pocket 
direct medical costs 
4.1.2.1.3 Indirect Costs 
The loss or reduction in productivity would be calculated based on daily 
earnings derived from the 2004 Hong Kong Census and Statistics Department 
website!� by the following formula: 
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Loss in Productivity per year 
= n o . of sick leave days reported by the subject via the interview x daily 
earnings derived from Jan - Mar 2004 Hong Kong Census and Statistics 
Department website 
Reduction in Productivity per year 
=Percentage of reduction in productivity reported by the subject via the 
interview x monthly earnings reported on the Jan - Mar 2004 Hong Kong 
Census and Statistics Department website x 12 
Hence, 
Annual total indirect costs = 
Loss in Productivity per year + Reduction in Productivity per year 
4,1,2.1.4 Total Costs 
Hence, 
Annual total costs 
=Annual total direct costs + Annual total indirect costs 
4.1.2.3 Impact of Costs of Type 2 DM to Local and Government Healthcare 
Expenditure 
As mentioned previously, it was estimated that 499,000 Chinese residents were 
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suffering from T2DM in HK and it was reported that the undiagnosed rate is 
60%^^, so the corresponding annual total costs and total direct medical costs of 
Type 2 DM and their impact to the local healthcare expenditure could be 
calculated using the following formula: 
No of diagnosed Chinese Type 2 DM patients in HK 
=499,000 X (1- undiagnosed rate) 
Annual total costs 
=annual total costs per patient x total no of diagnosed Type 2 DM patients in 
HK 
Annual total direct medical costs 
=annual direct medical costs per patient x total no. of diagnosed Type 2 DM 
patients 
Impact to local healthcare expenditure 
=annual total direct medical costs / total local healthcare expenditure 
Assuming that 93,6% of Type 2 DM patients in Hong Kong are using the HA 
healthcare SQrvices^ ,^ hence 
No. of Type 2 DM patients using HA healthcare service 
=No. of diagnosed Type 2 DM patients x 93.6% 
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Similarly, the total direct costs incurred at the HA and its impact to HA's 
healthcare expenditure could be calculated by the following formula: 
Annual total direct medical costs incurred at HA 
=annual direct medical costs per patient incurred at HA x No. of Type 2 DM 
patients using HA healthcare service 
Impact to HA's healthcare expenditure 
=annua l total direct medical costs / total local government healthcare 
expenditure 
Similarly, impact of all T2DM patients including both Chinese and non-
Chinese could be estimated by assuming 525,000 local residents were suffering 
from the disease and applying the same formulas as listed above. 
4.1.2.2 Statistical Analysis 
The subjects' characteristics, e.g. age, DM duration, body mass index, and 
waist-hip ratio and all data would be calculated as mean 士 s.d. or median using 
SPSS 9.0. The sex, comorbid diseases, types of complications were all 
expressed in frequencies. 
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4.1.3 Validity and Reliability of the Chinese Questionnaire 
Since the author developed a Chinese questionnaire, namely，，香港第二類型糖 
尿病,患者支出調查”，to collect direct medical incurred outside the public 
hospital, direct non-medical and indirect costs, it was necessary to test the 
content validity and test-retest reliability of the questionnaire. 
For the content validity, opinions from three experts, i.e. one DM specialist, 
one pharmacist and one study co-coordinator, on the questionnaire were 
obtained. Whereas for the test-retest reliability, due to limited resources, a 
convenience sample of twenty subjects who visited the clinic again within three 
months from the time of their first interview during the study period were 
invited to complete the other interview using the same questionnaire again. 
The author would then assess the correlations between the two sets of results. 
4.2 Results 
4.2.1 Subjects' Characteristics 
Two hundred and four Type 2 DM patients attended the diabetes mellitus 
outpatient clinic of the United Christian Hospital from Jan 2004 to May 2004 
were selected to join the study and 147 Type 2 DM patients were subsequently 
enrolled. The response rate was 72%. Fifty-four patients did not complete 
the face-to-face interview either because they did not show-up in the clinic, 
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refuse to join the interview, or found to be Type 1 DM patients (4 patients). 
Forty-five percent of patients were male with a mean age of 63 years old. 
61.3% of patients were over 60 years old as illustrated in Figure 33. The 
youngest patient diagnosed having Type 2 DM was 29 years old only. The 
mean duration of the disease was over 13.8 years, and 10.9% of patients were 
smokers. Twenty-six (17.7%) and 46 (31.3%) missing values were found for 
DM duration and waist-hip ratio, respectively. Since there were too many 
missing values for these two variables, they were dropped by the author. 
Details of the subjects' characteristics were listed in Table 18. 
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Table 18: Subjects' characteristics (n = 147) 
Mean 
s.d. Percent Median 
I (n) 
Men (66) 44.9 
Age (years) 63.0 11.3 64.0 
Body mass index (kg/m^) 24.3 3.9 24.1 
Smoking (16) 10.9 
Hypertension (78) 53.1 
Obesity (29) 19.7 
Overweight (26) 17.7 
Dyslipidemia (49) 33.3 
At risk of foot problems (32) 21.8 
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41 - 50 
1.4% 
10.9% 
71 80 y / ^ 
32.7% ! ^ ^ ^ ^ ^ ^ ^ 
/ 51 60 
25.2% 
\ j m m m “ 
61 - 70 ^ ^ H H H ^ r a ^ l ^ ^ 
27.2% ^ ^ ^ H S B B P ^ 
The socio-demographics of the subjects were shown in Table 19. Majority of 
the subjects were married and with low educational levels. Seventy-one 
percent of subjects had no schooling or primary educational levels. 73.5% of 
the patients were economically inactive. They were either retired persons or 
home-makers. Only 11.6% of the subjects had medical benefit. 
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Table 19: Subjects' socio-demographics (n=147) 
' Frequency Percent 
Marital status 
Never married 4 2.7 
Currently married 114 77.6 
Widowed 20 13.6 
Divorced / separated 7 4.8 
Missing (unreported) 2 1A 
Education 
No schooling / kindergarden 44 29.9 
Primary 60 40.8 
Secondary / matriculation 33 22.4 
Tertiary 9 6.1 





Economic active 39 26.5 
Economic inactive jQg ^ 
- R e t i r e d persons 48 44.4 
- H o m e - m a k e r s 
59 54.6 
.Others 1 0.9 
Medical Benefit 
Has no medical benefit 129 87.8 
Has medical benefit 11.6 
- M e d i c a l benefit provided by employers 10 58.8 
- S e l f - p a i d medical insurance 6 35.3 
- B o t h 1 5.9 
Missing (unreported) 1 0.6 
Medical Benefits Coverage (n = 17) 
Doctor consultation only 1 5.9 
Hospitalization only 3 17.6 




Doctor and dental consultation and 7 41.2 
hospitalization 
4.2.3 Comorbidity 
53.1% of patients had hypertension; 33.3% had dyslipidaemia; 37.4% were 
over-weighed or obese, 21.8% were at risk of foot problems, as shown in Table 
18. 
4.2.4 Complications 
The most common type of complications among our Type 2 DM patients was 
retinopathy (32.7%), followed by nephropathy (16.3%). Fifty-five percent 
had no complications, 28.6% of patients had microvascular complications only, 
and 6.1% of patients had macrovascular complications only, while over 10% of 





Table 20: Subject' complications (n = 147) 
Frequency Percent 
Microvascular complications 
Retinopathy 48 32.7 
Nephropathy 24 16.3 
Macrovascular complications 
Coronary heart disease 10 6.8 
Stroke 6 6.1 
Peripheral vascular disease 7 4.8 
. . . , • ....:,..:... . y，:；.‘.:； , '• • . ••‘ 、 - ； • . " • 
No complication . 镜 : , 55,1 
• . .. _ .彳：、 .； ^鄉锐 … . � . M - ‘ . � ， 
.、：： ‘ ‘：?•钱V� . 费： 
Microvascular complications only ： . ；:泣：连：-.:. 28.6 , 
‘ .： . • ； ：'. • , . V. • . , ••••；'. • • ； ‘ , ‘ . . 
‘ . ‘ ‘ •• ：•••• , • I .... • , • ‘ •‘ • i'" • • ‘ • • . 
‘ ； ‘ ‘ • • • • . - • • -
Macrovascular complications only 7 6.1 
,.•....、...’“."，’： , : I, ,...�-1- i • • ‘ • • ‘• • •. • . . • � - , � 
‘.：，.， ..... . . . ， I . . . . ’‘ ..’...：.‘ . . .，、. -,. . 
Both microvascular and macrovascular complications > 12 10.2 
• ‘ • . • ‘ • ‘ ' • • ! • • • ‘ . . . . . . . ’ - ‘ • • .‘ 




Figure 34: Subjects' complications (n = 147) 
micro and macro comp 
10.2% 
macro comp only 
6.1% ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 
comp o n l y ^ 55.1% 
28.6% 
4.2.5 Costs o f T V p e l D M 
4.2.5.1 Direct Medical Costs 




Table 21: Direct medical costs paid by the government and patient 
'： Mean s.d. Min. Max. Median 
I , (HK$) (HK$) (HK$) (HK$) 
Direct Medical Costs Paid by the Government 
Govt SOPC visit 4176 2472 700 12600 4200 
Govt GOPC visit 170 422 0 2580 0 
Family medicine 111 257 0 1075 0 
visit 
A&E visit 295 682 0 2850 0 
CNS visit 217 412 0 2380 0 
Allied health 1038 1849 0 15400 700 
service 
Injection and 4 34 0 350 0 
dressing visit 
Hospitalization m 4539 11653 0 66000 0 
general ward 





Hospitalization in 0 0 0 0 0 
HDU 
‘ - .‘ . •, • • •； / i ‘ ‘ •‘ • ', . , • • • •、 ， ’，. ... ；' . ‘•- . : . • 
Subtotal 10550 13031 1400 77140 5855 
“ • • • • • . • 
• , ‘ .. • - • • • • • - ‘ 
r . I ： . • I 
Direct Medical Costs Paid by the Patient 
Private practioner 278 746 0 6000 0 
visit .. 
Chinese 99 318 0 3000 0 
practioner visit 
Private A&E visit 13 106 0 1200 0 
Hospitalization at 0 0 0 0 0 
private hospital 
Consumables 699 817 0 4200 500 
Subtotal . 、；、, 1088 1137 : . \ � : \ 0 6400 740 
..i , 1. ., ！* . ,. . . • . . . * . •./、,. >. _ . . .. . • .、:.:、.*.:'-. . 
TOTAL 11638 ^3386 1700 77140 7080 
Note: 




Emergency, CNS = Community Nursing Service, ICU = Intensive Care Unit, HDU = High 
Dependency Unit 
The annual mean direct medical cost per patient was HK$11,638 土 13,386, and 
the median was HK$7’080，in which Government was the major payer. It paid 
for 90.6% of the direct medical costs, while the patients only paid for the 
remaining 9.4%. 
Among all the medical costs shouldered by the government, specialist 
outpatient clinic visits and hospitalizations were the major cost drivers, which 
contributed over 82% of the total direct medical costs paid by the government 
as shown in Figure 35. Although only 21.1% of patients were hospitalized, 
hospitalization costs accounted for 43.0% of the government direct medical 
costs. The annual mean total direct medical costs paid by the government per 




Figure 35: Major cost drivers for direct medical costs shouldered by the government (mean 
values) 
Other 
7.6% ^ ^ ^ ^ ^ ^ 




4.2.5.2 Drug Use 
Since the cost data of outpatient visits and hospitalizations published in the 
Gazette have included the cost of medications already, we took a conservative 
approach by not adding the costs of the medications into the direct medical 
costs described above. If we examined the drug costs separately, it was 
found that the average drug costs per subject were about HK$2,462 per year. 
Forty-two percent was spent on the antidiabetic agent; 17% on anti-
hypertensive agent; while 10% on anti-dyslipidemic agent. Details were 
shown in Figure 36. 
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Figure 36: Drug expense in Hong Kong Type 2 patients 
^ ^ ^ ^ ^ ^ / 26% I •O the r s 
17% 
It was also found that as many as 34% of the subjects needed to take both oral 
antidiabetic agent and insulin in order to control their diabetes. Only 40% of 
the subjects could be treated by antidiabetic agent only. Thirty-four percent of 
patients needed to take insulin to control their glucose levels. Details are 
shown in Figure 37. 
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Figure 37: Type of antidiabetic agents in Hong Kong Type 2 patients 
^ ^ 
/ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ ^ 40% • Subject taking oral anlidiabelic agent only 
Subject taking only 
• Subject taking both oral antidiabetic agent and 
\ • Subject taking no antidiabetic 
11% 
Combination therapy was very common in our subjects. 45% of the subjects 
took at least two different antidiabetic agents; 94% took at least two different 
anti-hypertensives. The mostly prescribed antidiabetic agent was metformin 
(88 subjects), followed by glyclazide (Diamicron) (39 subjects) and 
glibenclamide (Daonil) (33 subjects). Fewer took Acarbose, glipizide 
(Minidiab) and rosiglitazone (Avandia). 
4.2.5.3 Indirect Costs 
Indirect costs made only a relatively small contribution. Only eleven patients 
took sick leave from 1 — 10 days due to their diabetes and 10 patients reported 




patients claimed diabetes forced them to have premature retirement as early as 
50 years old. Patients participating in this study were the elderly and 
consequently relatively few were employed, so the costs associated with loss or 
reduction in productivity were relatively low. The indirect costs were 
calculated and shown in Table 22. 
In addition, 11 patients required their relatives and/or friends (i.e. carers) to 
take care of them and 7 of the caregivers were economically active. None of 
the patients required private nursing care. However, the costs for the 
caregivers were not calculated here since most of the patients could not provide 
estimation on how many leave days their relatives / friends took in the past one 
year in order to take care of them. 
Table 22: Indirect costs 
Mean s.d. Min. Max. Median 
(HK$) (HK$) (HK$) (HK$) 
Sick leave 84 442 0 4320 0 
costs 
Reduction in � 1979 10005 0 91200 0 
productivity 
costs 
• ' • - • — . . ‘ • - - • • • • • 




4.2.5.4 Total Costs 
In summary, the annual mean total cost for Type 2 DM per patient was 
HK$13,457 士 15，943，with direct costs contributed up to 87.9%. The 
Government was the major payer for the total costs. It contributed up to 
78.4% of the costs as shown in Figure 38. 
Figure 38: Major payer for the cost of Type 2 DM in Hong Kong (mean values) 
R out-of-pocket 
^ 9.5% 






In general, the total cost of T2DM increased with age as shown in Table 23 and 
Figure 39. Since fewer than 3 subjects were in age groups < 30，31-40 and > 
80, the corresponding data should be interpreted with care and might be 
excluded from evaluation. 
Table 23: Effect of age on annual total cost of T2DM in Hong Kong Chinese 
Age • ； M e a n • N s.d. Min. Max. 
group ！ (HK$) (HK$) (HK$) 
<30 14600 i • 14600 : ~ 1 4 6 0 0 
31 -40 ^ ^ 3 10864 
41 -50 9 m 16 12488 ^ 49374 
51 -60 12703 37 18727 ^ 105975 
61 - 70 15211 40 15297 56526 
71 - 80 14456 48 16233 1718 77210 
^ 2 ^ 5530 




Figure 39: Effect of age on annual total cost of T2DM in Hong Kong Chinese 
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It was also found that the direct medical costs increased dramatically if the 
patient had complications. When the patient developed microvascular or 
macrovascular complications only, the costs was 1.1 times, compared with 
those without complication. If the patient had both microvascular and 
macrovascular complications, the costs would be 1.3 times compared with 
those without complication as shown in Figure 40. The total mean 
government direct medical cost for those without complication was HK$9,781 
per year. When the patient developed both microvascular and macrovascular 
complications, the cost would jump to HK$13,193 per year. 
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Table 24: Effects of complications to the government direct medical costs of Type 2 DM 
patients in Hong Kong 
Complications Mean N s.d. Min. Max. 
(HK$) (HK$) (HK$) 
“ ~ n o complication 9 7 8 1 * ^ ‘ 12680 1400 77140 
microvascular 11059 42 12949 1 4 ^ 53845 
complication only 
macrovascular 10689 9 9 0 ^ X m 28755 
complication only 
m i c r o v a s c u l a r ^ 13193 15 17399 ^ 72240 
macrovascular 
complication 




Figure 40: Effects of complications to the government direct medical costs of Type 2 DM 
patients in Hong Kong 
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4.2.5.5 Impacts of Costs of Type 2 DM to Local Healthcare System 
As mentioned previously, the author decided to use a conservative and clinical-
based approach using the prevalence rate estimated by the Hong Kong 
Cardiovascular Risk Factor Prevalence Study, i.e. 9.8% for people aged 
between 25 and 74; and 21.7% for people aged 75 and above (assuming the 
prevalence of diabetes for people aged 75 and over is the same as that in men 
aged 65 - 74 years./i，to estimate the impacts of cost of T2DM to local health 




that aged over 75 was 0.3 million; and of which about 95% of population was 
Chinese�11 
Hence, 
Total no. of T2DM local residents (including both Chinese and non-Chinese) 
=4.6 million x 9.8% + 0.3 million x 21.7% 
=525,000 
Total no. of Chinese T2DM local residents 
=525,000 X 95% 
=499,000 
The undiagnosed rate of T2DM was assumed to be 60%.^^ 
Thus, 
No. of diagnosed T2DM local residents (including both Chinese and non-
Chinese) 
=525,000 X (100%-60%) 
=210,000 






Annual total costs of Type 2 DM patients in HK 
=annual total costs per patient (assuming it is the same as that for HK Chinese 
patients) x total no. of diagnosed T2DM local residents (including both Chinese 
and non-Chinese) 
= HK$13,457 x 210,000 
=HK$2,826 million 
Annual total costs of Type 2 DM patients in HK Chinese 
=annual total costs per patient x total no. of diagnosed Chinese T2DM local 
residents 
=HK$13,457 X 199,500 
=HK$2,685 million 
Annual total direct medical costs of Type 2 DM in HK 
=annual direct medical costs per patient (assuming it is the same as that for HK 
Chinese patients) x total no. of diagnosed T2DM local residents (including both 
Chinese and non-Chinese) 
= HK$ll ,638x 210,000 
=HK$2,444 million 
Annual total direct medical costs of Type 2 DM in HK Chinese 
=annual direct medical costs per patient x total no. of diagnosed Chinese 
T2DM local residents 




Since only total local healthcare expenditure in 2002 could be found (i.e. 
HK$65，365 million), the total direct medical costs in 2004 were discounted to 
the costs in 2002. By using 3% as the discounting rate (it is one of the 
commonly used discounting rates in the published literature), the direct medical 
cost of Type 2 DM in 2002 was estimated to be HK$2，593 million. 
Thus, 
Proportion of direct medical costs of Type 2 DM to total HK healthcare 
expenditure in 2002 
=(HK$2,593 million / HK$65，365 million) x 100% 
=3.9% 
Assuming 93.6% of Type 2 DM patients are now using the HA's healthcare 
services95， 







Annual total direct medical costs incurred at HA (Government) 
=annual direct medical costs per patient incurred at HA (assuming it is the 
same as that for Chinese T2DM local residents) x no. of diagnosed T2DM local 
patients using the HA's healthcare services 
=HK$10,550 X 196,560 
=HK$2,074 million 
Total HA healthcare expenditure in 2004 was reported to be HK$32,232 
million95，thus 
Proportion of direct medical costs of Type 2 DM at HA to total HA healthcare 
expenditure 
=(HK$2，074 million / HK$32,232 million) x 100% 
=6.4% 
4.2.5.5 Validity and Reliability of the Chinese Questionnaire, ”香港第二類 
型糖尿病患者支出調查” 
The content validity of the Chinese questionnaire was found to be acceptable. 
All three experts, i.e. the DM specialist, the pharmacist and the study nurse had 




> Appropriate questions were asked. 
> The questions could be understood clearly. 
> Wordings were fine (no cultural issue). 
> Length and format of the questionnaire were acceptable. 
The correlations for the test-retest reliability of the questionnaire were shown in 
Table 25. The correlations for most of the answers, except those for the 
Chinese practitioner fee, special food fee, consumable fee and reduction in 
productivity, were good. No patients had ever visited private A&E 
department, private nutritionist, nor were hospitalized in the private hospital, so 
it was easy for them to give definite answers for questions related to these areas 




Table 25: Test-retest reliability of the Chinese qustionnaire,，，香港第二類型糖尿病患者支出 
調查” 
Correlation P 
• •； ..、...•‘.. ， . 
. • ‘ • • • • •. 
r 
Times to private 0.95 <0.01 
practioner 
Private practioner fee 0.97 <0.01 
Times to Chinese 0.78 <0.01 
practioner 
Chinese practioner fee 0.25 0.313 
Times to private - -
nutritionist 
Times to private A&E - -
Private A&E fee - -
Times to private hospital - -
Special food fee 0.13 0.61 




Sick leave days 1.00 <0.01 
Reduce in productivity -0.08 0.747 
Relative care days 1.00 < 0.01 
Private nursing hours 1.00 < 0.01 
4.3 Discussions 
Outcomes research is an under-developed area in Hong Kong. The present 
study was the first attempt to evaluate the cost of Type 2 DM in Hong Kong 
and its impacts to local and the government healthcare budget. It provides 
information on health resource utilization, the non-medical costs associated 
with managing Type 2 DM patients and costs linked with loss or reduction in 
productivity of the patients, or people caring the patients. With limited 
clinical, epidemiological and expenditure data, this attempt was challenging. 
There are two underlying reasons for this. Firstly, the Hong Kong government 
has been interested in total budget expenditure, rather than budget allocation for 
individual disease, or medical interventions, so that there is little information 
on costs. Secondly, economic analyses reporting cost savings from reduced 
bed use are often criticized because savings are unlikely to be realized in 
practice. It is because budget allocation is often based on population and the 
associated bed-days in that area. Hospital administrators sometimes use these 
figures to fight for more resources, so they may maintain the bed use to full 
capacity by extending "unnecessary" bed-days. However, the author believes 




other purposes and do represent an economic benefit. 
Many cost-of-illness (COI) studies related to diabetes mellitus have been 
performed in different countries, such as the USA, Europe, Australia and urban 
China, over the last three decades. These COI studies have repeatedly 
suggested that there is a large economic burden associated with diabetes. 
However, it is typically difficult to compare cost estimates among different 
studies. One of the major reasons for this limitation is the data availability 
1 1， 
and differences in various methods utilized. Most importantly, we should 
focus on the economic impact of a disease to the country, not cost-to-cost 
comparisons among countries. It is obvious that the incidence and prevalence 
of any disease have an economic impact. The magnitude of this impact, 
however, is also determined by the level of social development within the 
population affected. For example, the economic impact of diabetes in China 
is not the same as that in the U.S. or in western European countries. China is 
a developing country. The majority of people with diabetes are in the middle, 
and productive years of age i.e. 45-65 years old. In contrast, more than half of 
all people with diabetes in the developed countries (e.g. the USA and western 
European countries), are > 64 years of age.^^ The economic impact of 
diabetes caused by loss in productivity, and premature mortality (i.e. indirect 
cost) may be greater in China than that in the USA and western European 
countries. In addition, in developing countries, diabetes is often diagnosed 
quite late and often until complications are developed. The economic impact 
contributed by direct medical costs can be huge since direct medical cost for 
diabetic patients with complications is much higher than those without 




the USA, Europe and Australia. However, the life expectancy in developing 
countries is often shorter than that in developed countries. This phenomenon 
may reduce the economic impact of diabetes in developing countries due to 
chronic nature of the disease. 
Technical advances in medicine will also influence the future economic impact 
of the disease. For example, better understanding of the etiology of diabetes 
may lead to the development of effective primary and secondary prevention 
programs, which would help to reduce the incidence and, therefore the 
economic impact of the disease. In contrast, the current trend of increased life 
expectancy and tendency towards obesity among the populations of developed 
countries may result in a significant increase in the incidence and prevalence of 
Type 2 DM in these countries, and the consequent economic effects will be 
determined by the responses of the health care community.''^ 
In short, the future economic impact of diabetes will be influenced by incidence 
and prevalence of the disease; and the overall level of economic and social 
development within each particular c o u n t r y . ! i 5 T h u s ， i t is essential to conduct 
country-specific cost-of-illness studies, in order to truly estimate the economic 
impact of the disease to the country. It can then help healthcare decision 
makers to make informed decisions on budget allocations for various diseases, 
and to track the cost-effectiveness of different disease prevention or treatment 
programs over years. 
The cost estimates for Type 2 DM of the present study were primarily based on 
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existing, selected general population data on healthcare use and disability, 
through the use of International Classification of Diseases (ICD) codes, which 
were then supplemented with the survey data, based on the reported 
experiences of subjects. This bottom-up, retrospective, observational, 
prevalence-based approach had two advantages. Firstly, all episodes or events 
where Type 2 DM was listed as a primary, secondary or tertiary factor was 
included into the analysis, in order to avoid underestimation. Secondly, it was 
a less expensive and more accurate method comparing with those studies using 
only survey data. 
Some of the subjects' characteristics of the present study were similar with 
those in the developed countries. For example, more than 50% of the subjects 
were over 60 years of age. Significant percentages of subjects were having 
various co-morbidities, such as hypertension (53.1%), obesity (19.7%) and 
dyslipidaemia (33,3%), which had led to the development of different kinds of 
complications. However, the percentages of various complications were 
differed from those observed in the developed countries. Retinopathy (32.7%) 
and nephropathy (16.3%) were the two major complications for our subjects. 
These figures were much higher than those found in the USA, or Europe. 
Only about 7-19% of diabetic patients had ophthalmic and 4-13% had renal 
nA 
problems in the USA ； and about 20% of those in Europe suffered from 
retinopathy and 20% had microaluminuria^'. In contrast, cardiovascular 
disease was the major complication of the diabetic patients in the USA. As 
much as 16-20% of diabetic patients in the USA had this complication.^'^ 
Similar pattern was found in the European diabetic patients (up to 20% had 




drug expenses on anti-hypertensive and lipid-lowering agents were spent in 
Europe (42% of total drug expenses^') than in Hong Kong (27% of total drug 
expenses), which were primarily targeted to reduce CVD complications. In 
addition, we also observed that there was a change in pharmacological 
treatment pattern for glycaemic control in Hong Kong. In 1998， 
sulphonylurea was the key antidiabetic agent for lowering glucose level in 
Hong Kong.113 Now, in the present study, majority of the prescriptions for 
glycaemic control was metformin (60%). It may be due to the effect of the 
results of the UKPDS No. 51 study in recommending metformin was a cost-
effective treatment for blood-glucose control in overweight Type 2 DM patients. 
The study results demonstrated that the reduction in the costs of treating the 
complications of diabetes offset the additional costs of therapy (i.e. metformin) 
which resulting in an overall net saving. 
The distribution of direct costs and indirect costs of Type 2 DM in Hong Kong 
Chinese was similar with that in the Chinese who lived in urban China^^ (i.e. 
Direct Cost: Indirect Cost » 9 : 1). However, the proportion of direct costs in 
HK Chinese was much higher than that in the USA '^^  or Australia^"^. It may be 
due to two reasons. Firstly, wages for the elderly in HK or urban China were 
lower than those in the USA or Australia, so the costs for loss in productivity 
(indirect costs) were lower. Secondly, the impact of Type 2 DM on premature 
mortality could not be assessed using a self-reported questionnaire in the 
present study. Thirdly, indirect costs incurred by the carers of the patients 
could not be estimated due to unavailability of data; and hence had not been 
included into the calculation. Thus, these may represent an underestimation 




Most importantly, due to the unique healthcare financing system in HK, the 
Government was shouldering a huge burden of the disease, i.e. over 78% of 
total cost of Type 2 DM, as majority of the patients suffering from chronic 
diseases, like Type 2 DM, would go to the public healthcare sector to seek for 
disease management and treatment. Unlike in many other countries, the 
burden was shared among the government, insurers, employers and patient 
themselves. This phenomenon became more prominent when we focused at the 
direct medical costs only. Based on the current estimates, the Government 
was shouldering over 90% of the direct medical costs of Type 2 DM, which 
representing up to 3.9% of total healthcare expenditure in 2002 (HK$2,593 
million = US$332 million; US$1 = HK$7.8 as HK dollar is pegged with US 
dollar under this exchange rate.) and 6.4% of the HA's healthcare expenditure 
in 2004 (HK$2,074 million = US$266 million). This level of spending was 
similar with that reported for urban China (3.9%)^^, Australia^^ (5%) and the 
western European countries^' (about 5%), and much lower compared with that 




Figure 41: Effect of cost of Type 2 DM to local healthcare expenditure 
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Nevertheless, the burden of diabetes is expected to continue to rise in the next 
thirty years due to our expanding and aging population. According to the 
Hong Kong Population Projections 2004-2033 ‘口，the population is estimated to 
increase from 6.8 million in 2003 to 8.4 million in 2033. The proportion of 
persons aged over 65 years will rise by 1.3 times from 12% in 2003 to 27% in 
2033 as shown in Figure 14. The expectations of life at birth will also 
increase from 84.3 in 2003 to 88.0 in 2033 for women and from 78.6 in 2003 to 
82.5 for men (Figure 15). According to the results, the cost of Type 2 DM 
increased with age. As a result, if the current healthcare financing system was 
not changed, or no new cost-effective prevention or treatment methods would 
be implemented, the burden of Type 2 DM on the Government would be further 




population; and tendency toward obesity among populations in HK. 
Major costs drivers, i.e. hospitalizations and outpatient visits, in managing Type 
2 DM patients were similar across all countries84’ 90,92,94 ^here data for cost of 
Type 2 DM were available. These two cost items accounted for over 80% of 
the healthcare utilization. In addition, like other countries, complications 
were a significant driver of the diabetes management costs. When the patient 
developed microvascular or macrovascular complications only, the direct 
medical costs were 1.1 times, compared with those without complication. 
If the patient had both microvascular and macrovascular complications, the 
costs would be 1.3 times compared with those without complication as shown 
in Figure 40. The total government direct medical cost for those without 
complication was HK$9,781 per patient per year. When the patient developed 
both microvascular and macrovascular complications, the cost would jump to 
HK$13,193 per patient per year. This increase in costs was predominantly 
due to increased costs associated with hospitalization. It is clear that 
strategies to minimize the development or progression of diabetes 
complications will reduce the burden of diabetes on the healthcare system, 
individuals with diabetes and their carers. 
Indirect costs contributed only a small percentage of the total costs of Type 2 
DM in HK. Only 7% of subjects reported their productivities were reduced by 
diabetes. This estimate was consistent with that observed in the USA. Like 
in the USA, for those individuals who were employed, having diabetes did not 
1 1 o 




claimed diabetes forced them to have premature retirement as early as 50 years 
old. Subjects participating in this study were elderly and consequently 
relatively few were employed, so the costs associated with loss or reduction in 
productivity were relatively low. However, with tendency to have younger 
diabetic patients (In the present study, the youngest Type 2 DM patient was 
only 29 years old.), the impact of indirect cost may rise in the near future. 
It was found that the characteristics of our subjects were comparable to those 
reported by the Hong Kong Department of Health's Population Health Survey, 
which meant our sample was a representative sample population. In our 
sample population, those over 60 years old were about 60% of total population, 
which was similar to those reported by the Department of Health's Population 
Health Survey 2003/200478. In this survey, those over 65 years old were 
about 50% and the Department of Health commented that this figure was likely 
an underestimation. In addition, the sex distribution in our sample population 
was also similar to the one reported in the Department of Health's Population 
Health Survey 2003/2004. In both samples, male contributed about 45% of 
total populations. 
In addition, the United Christian Hospital is one public hospital managed by the 
Hospital Authority in Hong Kong. All patients attending the public hospitals 
in HK are managed by the Hospital Authority similarly. The Hospital 
Authority has a goal to enhance system cost-effectiveness and improve 
population health through the development of community-oriented service 
models which means once the condition of a patient attending the specialist 
outpatient clinic becomes stable, he will be transferred to the Family Medicine 
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clinic or general outpatient clinic to have the follow-ups. Thus, the results 
obtained from the United Christian Hospital could be generalized to other local 
public hospitals. Nonetheless, the Hospital Authority is responsible for over 
93.6% of secondary care in HK. The results obtained from the United 
Christian Hospital could be extrapolated to estimate the cost of T2DM in HK. 
This 1-year retrospective design of the study had some limitations. Firstly, 
recall bias as could be a problem but since the data collection relied mostly on 
stored information at the electronic hospital database, and most cost figures 
collected from the Chinese questionnaire had good test-retest reliabilities, this 
problem was minor. Secondly, the individual drug costs and laboratory costs 
could not be estimated since they were all included into the fees for the 
outpatient visit or hospitalization published in the gazette. With the 
introduction of Hospital Authority's drug formulary in the near future (tentative 
in late 2005), the drug costs can be estimated more accurately. It is due to the 
fact that the fees published in the gazette will only cover costs for certain 
"general" drugs. The other "special" drugs, such as some newer anti-
hypertensives: losartan, amlodipine; antidiabetic agents: rosiglitazone, 
pioglitazone; lipid-lowering agents: simvastatin, atorvastatin, etc, will be 
needed to be paid by the patients themselves. By using a similar survey used 
in the present study, these "extra" drug costs can be collected by asking the 
patients directly. Thirdly, the indirect costs might have been underestimated 
since costs for deterioration in quality of life of the patients, costs for caregivers, 
and impact on premature mortality, were not examined. Thus, a future 




explore the cost of the disease in HK. Fourthly, the data obtained were quite 
dispersed and with large standard deviations; and thus should be interpreted 
with care. It might be due to the fact that the sample size was too small. 
Population study with larger sample size should be conducted in the future in 





Cost-effectiveness Analysis of Metformin + Rosiglitazone 
vs. Metformin + Glibenclamide for Type 2 DM Patient 
Whose Diabetes is not Adequately Controlled by 
Metformin Alone from a Payer's Perspective 
5.1 Methods 
5.1.1 Model Overview 
A decision-analytic model was developed to evaluate the direct medical costs, 
incurred by Metformin (M) + Rosiglitazone (G) or Metformin + Glibenclamide 
(G) in a 2-year period for a Type 2 DM Chinese patients in HK whose diabetes 
could not be adequately controlled by maximum dose metformin alone (i.e. 
line treatment failure of metformin). The model was shown in Figure 42. It 
was developed from a payer's perspective, incorporating only direct medical 
costs. 
In our systemic framework, we assumed all patients were treated to achieve the 




HbAlC value of < 7% ("controlled DM"). Patients who were uncontrolled 
(i.e. HbAlc > 7%) were treated based on the algorithm recommended by the 
UK Clinical Guideline^ 
The primary economic endpoint was the total 2-year cost of treatment to 
achieve the glycaemic goal (HbAlC < 7%) when starting with each of the two 
strategies (i.e. cost per controlled Type 2 DM patient). The effectiveness 
endpoint was the health-related quality of life (HRQOL) experienced by the 
patient at the end of year 2. To measure the HRQOL, we used the published 
data of Euroqol 5-D instrument for Type 2 DM p a t i e n t s . T h e Euroqol 5-D 
is a widely used and validated generic instrument that has five dimensions: 
mobility, self care, usual activities, pain/discomfort, and anxiety/depression. 
These endpoints were selected because according to the published literature 
patients with higher HbAlC levels and those using insulin were less satisfied 
with the treatment than other patients. Thus, it was important to conduct cost-
effectiveness analyses based on these endpoints in order to help decision 
makers to make an informed decision. 
Diabetic complications were not included primarily because the model was 
short term and assumed all patients would be treated to achieve the 
recommended glycemic goal (HbAlC < 7%)，thus drastically reducing the risk 
of developing complications and making the costs related to complications 




Figure 42: Decision-analytic model for management of Type 2 DM Chinese patients in HK in 
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5.1.2 Success, Failure and Discontinuation Rates 
The success (controlled, i.e. HbAlC < 7%) and failure (uncontrolled, i.e. 
HbAlC > 7%) rates; and the discontinuation rates due to adverse events or lack 
of efficacy were extracted from published literature. Few studies actually 
reported a proportion of patients achieving HbAlc < 7% (i.e. success / 
controlled rate), as the ADA recommendations are still relatively new. 
However, at least one study was available for each combination therapy. 
Mean dosage of each drug with the highest success rate on the literature was 
used. Percentage of patients with at least 1 adverse event for each 
combination therapy was also extracted from the literature. These rates served 
as the model transition probabilities as shown in Table 26 and Table 27. 
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Table 26: Success (controlled, i.e. HbAlC < 7%) and failure (uncontrolled, i.e. HbAlC > 7%) 
rates; and discontinuation rates used as base model transition probabilities for Type 2 DM 
Chinese patient whose diabetes is not adequately controlled by metformin alone in HK 
Transition probability 
Success rate Discontinuation rate 
Antidiabetic Literature Value Range Literature Value Range 
combination used in tested used in tested in Data Source 
therapy base in base sensitivity 
case sensitiv case analysis 
model ity model 
analysis 
0.1 0.01 Fonseca, Vivian 
hd-M + hd-R 0.28 0.28 . 0.00 0.00 
0.9 0.09 etal.�2i 
0 .1 - 0 . 0 1 -
hd-M + Id-G 0.64 0.64 0.07 0.05 M. Marre et a l . ' " 
0.9 0.09 
B.H.R. 
0.1 - 0.01 -
hd-R + hd-G 0.60 0.60 0.05 0.05 Wolffenbuttel et 
0.9 0.09 
al.丨 23 
md-M + hd-R 0.1 - 0.01 - George E. Dailey 
0.44 0.44 0.06 0.06 





a. hd represents high dose. Id represents low dose. 
b. hd-M = high dose of metformin (metformin 2500 mg daily); md-M = medium dose of 
metformin (metformin 2000 mg daily) Id-M = low dose of metformin (metformin 500 mg daily) 
c. hd-R = high dose of rosiglitazone (rosiglitazone 8 mg daily); Id-R = low dose of rosigitazone 
(rosiglitazone 4 mg daily) 
c. hd-G = high dose of glibenclamide (glibenclamide 10 mg daily); Id-G = low dose of 
glibenclamide (glibenclamide 5 mg daily) 




Table 27: Percentage of patients with at least one adverse event for each blood glucose 
lowering combination therapy 




combination Data Source 
therapy Value used Range tested in 
Literature in base case sensitivity 
model analysis 
hd-M+hd-R 0.78 0.78 0.1 - 0 . 9 Fonseca, Vivian et al.'^' 
hd-M + Id-G 0.52 0.52 0.1 - 0 . 9 M. Marre et a l . ' " 
hd-R + hd-G B.H.R. Wolffenbuttel et 
0.62 0.62 0.1 - 0 . 9 
a l . � 
md-M+ hd-R + hd-
0.53 0.53 0.1 - 0 . 9 George E. Dailey III et al.'^' 
G 
Note: 
a. hd represents high dose. Id represents low dose. 
b. hd-M = high dose of metformin (metformin 2500 mg daily); md-M = medium dose of 
metformin (metformin 2000 mg daily) Id-M = low dose of metformin (metformin 500 mg daily) 
c. hd-R = high dose of rosiglitazone (rosiglitazone 8 mg daily); Id-R = low dose of rosigitazone 




c. hd-G = high dose of glibenclamide (glibenclamide 10 mg daily); Id-G = low dose of 
glibenclamide (glibenclamide 5 mg daily) 
5.1.3 Resources Use and Costs 
Since the UK Clinical Guideline ^^ ^ and the ADA Clinical Practice 
Recommendations for management of Type 2 diabetes were widely 
practiced in Hong Kong, they were served as the basis for determining resource 
use. 
Resource use included specialist outpatient clinic visits (SOPC), patient 
education, foot and eye exam visits, laboratory tests and medications. 
Frequencies of the visits were determined by the status of the patients in 
accordance with the international guidelines and local practice: 
SOPC visit: 
- controlled DM by any antidiabetic agent combination therapy, without AE: 
follow-up SOPC visit every 6 months 
- controlled DM by any antidiabetic agent combination therapy, with AE: 
follow-up SOPC visit every 4 months 
- controlled DM by any insulin-based therapy: 




- uncontrolled DM: follow-up SOPC visit every 3 months 
- distincontinued DM: follow-up SOPC visit every 3 months 
Diabetes education class: 
- Controlled DM: once every 12 months 
- Uncontrolled DM: once every 6 months 
Eye exam: 
- All patients: once every 12 months 
Foot exam: 
- All patients: once every 12 months 
Laboratory tests: 
- All patients - HbAlc: once every 3 - 4 months 
All patients - liver function test, renal function test, lipid profile (cholesterol 
and triglycerides), urine protein, blood glucose, complete blood count: 




Local costs for the routine medical care were used in the analysis and were 
based on the HK SAR Government Gazette. The costs were summarized in 
Table 28. Medication costs were based on the costs at one public hospital in 
HK (i.e. United Christian H o s p i t a l ) a n d were listed in Table 29. Key 
adverse events requiring hospitalizations and the associated costs were shown 
in Table 30. An annual discount rate of 3% for model costs was used in the 
base case model. 
Table 28: Routine medical care costs for Type 2 DM Chinese patients in HK 
Medical Care Cost per visit (HK$; 2004 Data Source 
values) 
SOPC visit ‘ 700 HK SAR Government Gazette'"' 
Diabetes education class 700 HK SAR Government Gazette咖 
Eye exam visit 700 HK SAR Government Gazette朋 
Foot exam visit 700 HK SAR Government Gazette"" 
Note: 
a. Laboratory tests costs were not listed and calculated separately since they were included in 




Table 29: Costs for blood glucose lowering agents for Type 2 DM Chinese patients in HK 
Blood Gluose Lowering Monthly Cost Data Source 
Agents (HK$, 2004 
values) 
Metformin 500 mg daily (Id- 1.80 HA Drug Formulary''' 
M) 
Metformin 2000 mg daily 7.20 HA Drug Formulary'^' 
(md-M) 
Metformin 2500 mg daily 9.00 HA Drug Formulary'" 
(hd-M) 
Glibenclamide 5 mg daily 1.08 HA Drug Formula ry� 
(Id-G) 
Glibenclamide 10 mg daily 2.16 HA Drug Formulary'^' 
(hd-G) 
Rosiglitazone 4 mg (Id-R) 225.00 HA Drug Formulary'^' 
Rosiglitazone 8 mg (hd-R) 375.00 HA Drug Formulary'^' 
Insulin 15 U/day (Id-insulin) 49.90'' Chow C. C. et al.'^^ and “Cost of Type 
2 DM Chinese in HK" (present study) 
Insulin 60 U/day (hd- 199.60'' Chow C. C. et a l . ' " and "Cost of Type 2 





a. hd represents high dose, md represents medium dose. Id represents low dose. 
b. Insulin dosages were extracted from a local published study. When insulin was used alone, 
a higher dosage was required. However, when it was used in combination with other 
antidiabetic agent, a lower dosage was required.'" The costs of insulin were estimated from 




Table 30: Key adverse events (AE) requiring hospitalizations for Type 2 DM Chinese patients 
inHK 
Key AE associated Incidence rate of Cost per AE Data 
with each blood AE episode Source 
glucose lowering (HK$; 2004 
agents values) 
Severe hypoglycamia 9900® 
-Glibenclamide 1.4% UKPDS Group'" 
-Insulin 1.8% UKPDS Group'" 
Lactic acidosis 19800'' 
-Metformin 0.003% Bristol-Myers 
‘ Squibbi34 
Note: 
a. Assume 100% of patients with severe hypoglycaemia 3-day hospitalization (based on expert 
opinion). Cost of hospitalization at a public hospital per night is HK$3,300.'°' 
b. Assume 100% of patients with lactic acidosis requires 6-day hospitalization (based on results 




5.1.4 Health-Related Quality of Life (HRQOL) 
As the above mentioned, we used the published data of Euroqol 5-D instrument 
for Type 2 DM p a t i e n t s t o estimate the HRQOL of our patient at the end of 
year 2. The Euroqol 5-D is a widely used and validated generic instrument 
that has five dimensions: mobility, self care, usual activities, pain/discomfort, 
and anxiety/depression. The set of possible values has a range of -0.549 to 1， 
where 1 indicates perfect health, 0 indicates death, and -0.549 indicates the 
worst possible health state that is view by the general public as considerably 
worse than death. It was found that patients using insulin were less satisfied 
with the treatment than other patients. The published data were shown in 
Table 31. 
Table 31: Quality of life as reported by type 2 diabetic patients 
Treatment EQ5D utility score" Data Source 
Diet and exercise only 0.79 (0.26) Redekop, W. Ken et a l . ' " 
Oral therapy only 0.76 (0.25) Redekop, W. Ken et a l . ' " 
Insulin only or combined 0.63 (0.30) Redekop, W. Ken et a l . ' " 
Note: 




5.1.5 Base Case Analysis 
Using the transition probabilities selected for the base case, as well as the cost 
and effectiveness data, we calculated the cost-effectiveness for each 
combination therapy, i.e. M+R, and M+G, using a set of software, DATA 3.5, at 
the end of year 2. An annual discount rate of 3% for model costs was used in 
the base case model. 
5.1.6 Sensitivity Analyses 
We conducted both one-way and two-ways sensitivity analyses to assess the 
robustness of the model result. Since the cost of rosiglitazone was very high 
and the chance of M+R to achieve glycemic goal (i.e. success rate) was quite 
low in the published literature, we believed that these two variables imposed 
the greatest impacts to the model. For the one-way sensitivity analysis, we 
would vary the probability of M+R and M+Q to achieve the glycemic goal 
from 10% to 90%. For the two-way sensitivity analysis, we would combine 
the effects of these two variables with the above mentioned sensitivity ranges to 
test the robustness of the results. In addition, we would also reduce the cost of 
R by 90% and ran a cost-effectiveness analysis again in order to evaluate the 





5.2.1 Base Case Model - CE Analysis: cost per controlled T^pe 2 DM 
patient 
Adding glibenclamide to metformin was more cost-effective for management 
of Type 2 DM patients in a 2-year period whose diabetes could not be 
adequately controlled by maximum dose of metformin alone, compared with 
adding rosiglitazone to metformin. The cost per controlled Type 2 DM patient 
for M+R was HK$ 17,645 while that for M+G was HK$ 11,909 in 2-year period. 
The incremental cost was HK$5,736. 
Key driver for the medical care cost for Type 2 DM patients was the clinic visit 
cost. It contributed up to 86% and 97% of the total cost, in the M+R arm and 
M+G arm, respectively. It was obvious that when R was used, the 
contribution of drug cost to the total cost became high. R could contribute up 
to 54% of the total cost. Adverse event costs were minimal and represented < 




5.2.2 Sensitivity Analysis- CE Analysis: cost per controlled Type 2 DM 
patient 
The most sensitive model variables within each sub-tree were the success 
(controlled) rates of the combination therapies, and the drug costs, assuming 
the clinic visit costs (HK$700) remained constant. Over 80% of the clinic 
visit costs incurred at the public hospital in HK were contributed by salaries of 
the hospital staff and these costs were difficult to be changed based on the 
current situation in HK. Thus, the variation of clinic visit costs was not 
considered here. The sensitivity analysis results of varying the success rates 
of M+R and M+G from 10-90% were shown in Figure 43 and Figure 44， 
respectively. Both sensitivity analysis results clearly demonstrated that our 
base-case model result was robust, i.e. M+R was dominated by M+G 
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Figure 43: One-way sensitivity analysis by varying success rates of M+R 
Sensitivity Analysis on 
success rate of hd-M + hd-R 
$18 0K • Add hd-R (hd-M+hd-R) 
” • Add Id-G (hd-M+ld-G) 









$11.7K I ""“""” 7 1 
0.10 0,30 0.50 0.70 0.90 
success rate of hd-M + hd-R 
Figure 44: One-way sensitivity analysis by varying success rates of M+G 
Sensitivity Analysis on 
success rate of hd-M + Id-G 
$17,700.0 f • • • • Add hd-R (hd-M+hd-R) 
$ 16,700.0 - • A d d Id-G (hd-M+ld-G) 
« $丨5’7。。.。-\^ ^^  
^ $14,700.0 — 
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In addition, even the cost of R was reduced by 90%, M+G was still a more 
cost-effective option. Under this condition, cost per controlled Type 2 DM 




5.2.3 Base Case Model - CE Analysis: cost per EQ5D utility score 
As a reference, we also conducted a cost-effectiveness analysis incorporating 
health-related quality of life (HRQOL) element. EQ5D utility score was used 
as a measure of HRQOL for Type 2 DM patient. The set of possible values 
has a range of -0.549 to 1, where 1 indicates perfect health, 0 indicates death, 
and -0.549 indicates the worst possible health state that is view by the general 
public as considerably worse than death. 
As shown in Figure 45，adding glibenclamide to metformin was more cost-
effective for management of Type 2 DM patients in a 2-year period whose 
diabetes could not be adequately controlled by maximum dose of metformin 
alone, compared with adding rosiglitazone to metformin. The cost-
effectiveness ratio in 2-year period for M+R was HK$17,500 per EQ5D utility 




Figure 45: Cost-effectiveness analysis of M+R vs. M+G 
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5.2.4 Sensitivity Analysis- CE Analysis: cost per EQ5D utility score 
Like the cost-effective analysis in estimating cost per controlled Type 2 DM 
patient, the most sensitive model variables within each sub-tree were the 
success (controlled) rates of the combination therapies, and the drug costs, 
assuming the clinic visit costs (HK$700) remained constant. Over 80% of the 
clinic visit costs incurred at the public hospital in HK were contributed by 
salaries of the hospital staff and these costs were difficult to be changed based 
on the current situation in HK. Thus, the variation of clinic visit costs was not 
considered here. The sensitivity analysis results of varying the success rates 
of M+R and M+G from 10-90% were shown in Figure 46，Figure 47 and 
Figure 48. All sensitivity analysis results demonstrated that our base-case 




Figure 46: One-way sensitivity analysis by varying success rates of M+R 
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Figure 47: One-way sensitivity analysis by varing success rates of M+G 
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Figure 48: Two-way sensitivity analysis for varying success rates of M+R and M+G 
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As mentioned in the first part of the present study (Chapter 4)，like other 
countries, complication was a significant driver of the diabetes management 
costs. When the patient developed microvascular or macrovascular 
complications only, the direct medical costs were 1.1 times, compared with 
whom without complication. If the patient had both microvascular and 
macrovascular complications, the cost would be 1.3 times, compared with 
whom without complication. It is clear that strategies to minimize the 
development or progression of diabetes complications will reduce the burden of 
diabetes on the healthcare system, individuals with diabetes and their carers. 
The findings from the UKPDS indicate that any reduction in a person's average 
HbAlC level is likely to reduce the risk of complications, especially the 
microvascular complications. As a result, all international guidelines 
recommend reducing the Type 2 DM patient's HbAlC level to < 7%. At the 
same time, the patient's quality of life should also be considered as it will affect 
his compliance to the pharmacological treatment. 
Metformin was widely prescribed in HK currently for lowering the blood 
glucose level of Type 2 DM patients as shown in the present study. However, 
the UKPDS study indicated that after 3 years, only 50% of Type 2 DM patients 
were adequately controlled with a single antidiabetic agent, and after 9 years, 
this percentage had decreased to Is addition of which antidiabetic 
agent, SU or TZD more cost-effective, if the patient's diabetes cannot be 
adequately controlled by metformin alone? From the results of the present 




compared with adding rosiglitazone (TZD) to metformin, for the management 
of Type 2 DM Chinese patients in HK. The cost per controlled Type 2 DM 
patient for M+R was HK$ 17,645 while that for M+G was HK$ 11,909 in 2-year 
period. The incremental cost was HK$5,736. 
In addition, even if we also took patient's quality of life into consideration, 
M+G was still a more cost-effective option. The cost-effectiveness ratio in 
2-year period for M+R was HK$ 17,500 per EQ5D utility score, while that for 
M+G was HK$ 14,893 per EQ5D utility score. However, we should take this 
result as a reference only because health-related quality of life (i.e. EQ5D 
utility score) is always subjected to cultural difference. EQ5D utility score 
obtained from the western European country may not be applicable in the 
Chinese population. Future study to investigate Chinese patients' 
satisfaction in using insulin and other antidiabetic agents is needed. 
It was not surprising to see that key driver for the medical care cost for the 
management of Type 2 DM patients was the clinic visit cost. It contributed up 
86% and 97% of the total cost, in the M+R arm and M+G arm, respectively. 
If the patient's diabetes is controlled with no major adverse events, he can 
reduce his clinic visit to every 6 months. The total medical care cost can then 
be significantly decreased. Choosing an antidiabetic agent in this profile is 
thus very important for clinicians and healthcare decision makers. 
Our findings suggested that combination therapy of M+G is more cost-effective 
than M+R in short-term, for Type 2 DM patients whose diabetes cannot be 




that SU will cause severe hypoglycemia, so the associated hospitalization costs 
are very high. However, we found that in the present analysis, adverse event 
costs were minimal and represented < 3% of the overall cost of treatment. It 
was due to primarily the low incidence rates of the adverse events. 
Nonetheless, we still should interpret the results of the present analysis with 
care due to the following reasons: 
> Only short-term clinical data exist for M+R, and even for M+G, at this 
point in time. Moreover, the success, failure, discontinuation, and 
adverse event rates used in the model were extracted from studies which 
were conducted in non-Chinese populations. All were conducted in the 
USA and Europe. The rates for Chinese Type 2 DM patients may be 
different. 
> The UKPDS showed that the decrease in efficacy of oral antidiabetic 
agents over time that is related to loss of B-cell function in the pancreas 
has a major influence on cost-effectiveness. This is an area where 
rosiglitazone may have a long-term benefit over traditional medications. 
> Another potential issue for the model is the generalisability to other 
countries or health systems. While we believe that the model structure is 
broadly applicable, it must be noted that Hong Kong specific resource 
utilization patterns and HK drug prices were used exclusively. Thus, the 
model results should not be extrapolated outside HK without first tailoring 




Medication compliance, diabetic complications, lipid effects and weight gain 
were not included in the model, and may, therefore, represent potential 
limitations. However, due to the short-term time horizon of the model, we 
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Chapter 6. Conclusions 
Accurate information on diabetes costs is vital to inform and guide resource 
allocation decisions and to provide baseline information for future comparisons 
and evaluations of the effect of public health policies and intervention. The 
present study was the first time we had local data which were specific to our 
healthcare system. It was clear that the government was the major payer in 
managing Type 2 DM patients in HK in which it shouldered over 90% of the 
direct medical costs. The onsets of microvascular and macrovascular 
complications rose the burden of the disease dramatically through increased 
hospitalizations and specialist outpatient clinic visits. Any innovative 
treatment strategies reducing the rate of the complications, is expected to lower 
the burden of the disease significantly. Most importantly, it can help to relieve 
the local government budget pressure, or the resources saved can be used in 
other therapeutic areas in order to maximize the overall health of the 
community. 
We developed an economic model that incorporated both the glycemic goals 
recommended by the American Diabetes Association, and the algorithm of the 
UK Clinical Guidelines for the management of blood glucose in Type 2 DM 
patients, in order to project and evaluate the cost-effectiveness in short-term (2-
year) for two different combination strategies (metformin [M] + rosiglitazone 
[R], and metformin + glibenclamide [G]) for patients whose diabetes could not 
be adequately controlled by metformin alone. Based on the results of our 
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decision analysis model, with its underlying assumptions and data, combination 
therapy M+G is more cost-effective than M+R. The cost per controlled Type 
2 DM patient for M+R was HK$ 17,645 while that for M+G was HK$ 11,909 in 
2-year period. The incremental cost was HK$5,736. These findings should 
be re-evaluated as soon as additional evidence becomes available from the 
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• 學 生 • 退 休 人 士 •家庭主婦 • 其 他 
2.你從事那個行業？ 
• 製 造 業 口建造業 •批發，零售，進出 
口貿易，飲食及酒店業 
•運輸，倉庫及通 •金融，保險，地產及 •社區，社會及個人 
訊業 商用服務業 服務業 
• 其 他 
3.你的職業組別？ 
•經理及行政級人員 口專業及輔助專業人員 • 文 員 
• 服 務 工 作 及 商 店 銷 . • 工 藝 及 有 關 人 員 •機台及機器操作員 
售人員 及裝配員 





















• 學 生 •退休人士 •家庭主婦 • 其 他 ， 往 問 
題12 
10.照顧的親屬或朋友是從事那個行業？ 
•製造業 •建造業 口批發，零售，進出 
口貿易，飲食及酒店業 
•運輸，倉庫及通 •金融，保險，地產及 •社區，社會及個人 
訊業 商用服務業 服務業 
• 其 他 
11.那一位親屬或朋友的職業組別？ 
•經理及行政級人員 •專業及輔助專業人員 • 文 員 
•服務工作及商店銷 •工藝及有關人員 •機台及機器操作員 
售人員 及裝配員 














•從未結婚 • 已 婚 • 喪 偶 • 離 婚 / 分 居 
2.你的教育程度？ 
• 未 受 教 育 / • 小 學 • 中 學 / 預 料 •專上教育 
幼稚園 
3.你有否享有醫療福利或醫療保險？ 
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